Epitranscriptome: Review of Top 25 Most-Studied RNA Modifications

Viktoriia A. Arzumanian *,†, Georgii V. Dolgalev *,†, Ilya Y. Kurbatov , Olga I. Kiseleva and Ekaterina V. Poverennaya

Institute of Biomedical Chemistry, 119121 Moscow, Russia

* Correspondence: arzumanian.victoria@gmail.com (V.A.A.); dynev.aw@gmail.com (G.V.D.);
Tel.: +7-960-889-7117 (V.A.A.); +7-967-236-36-79 (G.V.D.)
† These authors contributed equally to this work.

Abstract: The alphabet of building blocks for RNA molecules is much larger than the standard four nucleotides. The diversity is achieved by the post-transcriptional biochemical modification of these nucleotides into distinct chemical entities that are structurally and functionally different from their unmodified counterparts. Some of these modifications are constituent and critical for RNA functions, while others serve as dynamic markings to regulate the fate of specific RNA molecules. Together, these modifications form the epitranscriptome, an essential layer of cellular biochemistry. As of the time of writing this review, more than 300 distinct RNA modifications from all three life domains have been identified. However, only a few of the most well-established modifications are included in most reviews on this topic. To provide a complete overview of the current state of research on the epitranscriptome, we analyzed the extent of the available information for all known RNA modifications. We selected 25 modifications to describe in detail. Summarizing our findings, we describe the current status of research on most RNA modifications and identify further developments in this field.

Keywords: RNA modifications; epitranscriptome; RNA

1. Introduction

The discovery of the first modification of RNA occurred in 1957, when the “fifth nucleotide”, pseudouridine, was identified [1]. By 1995, 93 naturally occurring modified nucleosides were identified primarily in two large classes of RNA, rRNA and tRNA. However, knowledge of the exact frequency and function of the majority of these modifications was obscure due to the limits of the available technology [2]. In the last 20 years, with the advent of technologies for next-generation sequencing (NGS) and improvements to liquid chromatography–mass spectrometry (LC-MS/MS), more than hundreds of various modifications have been characterized across all RNA species and domains of life [3].

It is now widely appreciated that RNA modifications are significantly more numerous and common in cellular RNA than thought initially—The current release of the main database for cataloging RNA modifications, MODOMICS, lists slightly more than 300 such modifications [4]. These modifications can be relatively simple, involving, for instance, only an addition of a methyl group, or complex, as is the case with 5-methoxycarbonylmethyl-2-thiouridine, which is installed in substrate RNA in a multistep process by a group of enzymes [5]. Despite the large number of known RNA modifications, only a few of the most popular ones continue to be the subject of general reviews on this topic.

Many RNA modifications are indispensable for the function of RNA species. They are required for proper folding [6], transcription [7], splicing [8], translation [9], RNA transport [10], and immune responses [11]. Many such modifications are always present in RNA in specific positions. However, it is being increasingly reported that some RNA modifications are dynamic, affecting the behavior of RNA molecules in a temporal and

https://www.mdpi.com/journal/ijms
context-sensitive manner [5]. While this phenomenon has only recently been discovered, such dynamic behavior has already been associated with important cellular processes, for instance, response to heat shock [12] or different toxins [13].

The significance of the research on RNA modifications is highlighted by their tight association with diseases of various natures [14]. Particular attention has been devoted to the role of modifications in cancer, where disbalances of RNA modification levels are often linked to a more severe prognosis [15]. Aberrant RNA editing has been associated with hepatocellular carcinoma (HCC) [16], Hodgkin lymphoma [17], and many other types of cancer [18]. On the other hand, the recent success of mRNA-based vaccines against SARS-CoV-2 is mainly due to the N1-methylpseudouridine modification that increases the translational efficiency of vaccinal mRNA [19].

The presented facts signify the importance of research on RNA modifications, but most of the attention in recent years has been paid to only a handful of well-established modifications. At the same time, our knowledge of other modifications is rapidly growing. Annotating modifications with data on their distribution and function is critical to obtain the global picture of the role and prevalence of RNA modifications. Accordingly, in this review, we analyzed the popularity of known modifications as evidenced by the number of relevant articles and provided a comprehensive description of the frequency of occurrence, distribution, biological function, connection to diseases, and detection methods for 25 modifications. Together, this information paints the role of RNA modifications as widely occurring in all RNA classes from all domains of life and as key players in cellular processes.

2. Current Status of Research on RNA Modifications

To understand the current level of research on RNA modifications in total and per individual RNA modifications, we used the full name of each modification provided in the MODOMICS database [4] together with the keyword “RNA” via the Entrez API to estimate the number of articles in the PubMed database mentioning the modification name in the title or the abstract. We then manually reviewed the results starting from the top (RNA modifications with the most articles) and removed modifications that were either incorrectly interpreted by the Entrez search engine (indicated by a significantly smaller number of articles when querying PubMed directly) or modifications primarily investigated outside the context of endogenous cellular RNA, for example, 4-thiouridine, which is a major part of multiple NGS-based techniques [20]. As a result, we discovered 45 modifications that had ten or more relevant articles (Table S1). Since we used strict search criteria to minimize the number of irrelevant findings, our figures likely represent a conservative estimate. They do not include all publications related to RNA modifications.

The research on RNA modifications is an actively developing area, as evidenced by a continuous increase in the number of relevant articles in recent years (Figure 1). Our search strategy correctly identified the most well-established RNA modifications as the modifications with the largest number of relevant articles, both per year (Figure 1A) and in total (Figure 1B). The modification with the most attention growth in recent years is N6-methyladenosine, which is not surprising considering its abundance in mRNA, its now-established strong connection to cancer processes, and a plethora of high-throughput methods for its detection (see below). While other modifications demonstrated more negligible growth, it is noteworthy that the number of articles related to modifications outside the top five has been growing in recent years (Figure 1A).
Figure 1. (А) Number of published articles that are strongly related to specific RNA modifications in the PubMed database per year. (B) Total number of articles on specific RNA modifications in the PubMed database.

3. RNA Modifications at Large

To provide a justified overview of the current state of the characterization of individual RNA modifications, we selected the top 25 RNA modifications with the most relevant articles in our list for further characterization. We collected all the available information regarding their frequency of occurrence, distribution in RNA, established biological function, association with various diseases, and specific methods designed to detect them in RNA (Table 1). Our goal was to spotlight not only the well-established modifications, but also the less popular ones that are usually omitted from most general reviews, despite the recent indications of their vital biological roles and frequent occurrence in endogenous RNA.

Table 1 reveals that selected modifications affect distinct bases in similar proportions, which aligns with the data for all known modifications [4]. Nucleotides are modified by specific enzymes such as RNA-modifying proteins (RMPs): writers, erasers, and readers. RMPs modify nucleotides, changing their properties and functions. Modifications to nitrogenous bases can either stabilize or destabilize the base pairs to trigger refolding into more stable structures or weaken them. The influence picture of modifications on RNA structures is only just beginning to develop due to a lack of methods. The existing experimental methods (X-ray crystallography and NMR spectroscopy) are resource-intensive, and there are not many efficient computational methods that are able to predict complex motifs or even three-dimensional conformations of RNA from sequence data [118].

In terms of the occurrence of RNA modifications across domains of life, most modifications are present in all three domains with a few exceptions, for instance, archaeosine, which is detected only in archaea [102]. This is consistent with the theory that modified RNA existed well before the advent of cellular life [119].
Table 1. Available information on selected RNA modifications; the table is filtered by the frequency of occurrence of modifications in articles.

| Modification           | Code | Base | Domains | RNA Classes | Location and Frequency | Function                                                                 | Methods           | Diseases                        | Ref.        |
|------------------------|------|------|---------|-------------|------------------------|--------------------------------------------------------------------------|-------------------|---------------------------------|------------|
| N6-methyladenosine     | m6A  | A    | All     | rRNA, tRNA, mRNA, miRNA, lncRNA, circRNA, snRNA | mRNA: enriched in 5’-UTRs, around stop codons, and in 3’ UTRs             | mRNA: regulates splicing events, induces mRNA instability, increases translation efficiency; lncRNA: plays a role in lncRNA-mediated transcriptional repression | DRS, HPLC, MeRIP-seq, MiCLIP | Osteoporosis, HCC, obesity      | [21–27]   |
| Inosine                | I    | A    | All     | tRNA, mRNA, miRNA | tRNA: p. 34, 37, 57; mRNA: dsRNA regions | tRNA: required for wobble codon recognition; mRNA: affects stability and localization, can change protein sequence | LC-MS/MS, RT-PCR, DRS, de novo RNA-seq | HCC; gastric, colorectal, esophageal, glioblastoma, and lung cancers | [28–33]   |
| Pseudouridine          | Ψ or Y | U    | All     | rRNA, tRNA, snRNA, Mt-tRNA, scaRNA, snRNA, miRNA, lincRNA | tRNA: p. 55; mRNA: 5’UTR, 3’UTR, CDS | rRNA: plays a role in ribosome assembly and translational fidelity; tRNA: increases stability | Pseudo-Seq, DRS, PSI-seq, CeU-Seq, Ψ-Seq, RB5-seq | Prostate, breast, and lung cancers; HCC | [34–41]   |
| 7-methylguanosine      | m7G  | G    | All     | miRNA, tRNA, mRNA, tRNA | rRNA: SSU G1639 (in humans); tRNA: p. 46; mRNA: 4522 clusters within 2318 mRNAs in 293T cells | tRNA: increases stability; mRNA: regulates translation | m7G-MeRIP-seq, m7G-seq, DRS, m7G-MiCLIP-seq, m7G-MaP-seq | HCC, PAD, lung cancer | [35,42–48] |
| Dihydrouridine         | D    | U    | All     | tRNA, mRNA, snoRNA | tRNA: p. 16, 17, 20, 20a, 20b, 47; mRNA: 130 sites in 112 transcripts in S. cerevisiae; snoRNA: 48 sites in 23 snoRNA in S. cerevisiae | tRNA: destabilizes the structure; mRNA: affects splicing and translation | D-seq, Rho-seq, LC-MS | Lung cancer                     | [49–53]   |
| N1-methyladenosine     | m1A  | A    | All     | rRNA, tRNA, mRNA, lncRNA | tRNA: p.1322 in 285; tRNA: p. 9, 14, 16, 22, 57, 58; mRNA: rare | tRNA: ensures proper folding; mRNA: increases stability and proper folding | ARM-seq, m1A-seq, m1A-quant-seq, m1A-ID-seq, m1A-seq-SS, m1A-seq-TGIR, m1A-MAP, m1A-IP-seq | HCC; cervical, pancreatic, breast, and ovarian cancers | [17,54–59] |
| Queuosine              | Q    | G    | Bacteria, eukaryotes | tRNA | tRNA<sub>Thr</sub>, tRNA<sub>His</sub>, tRNA<sub>Asn</sub>, tRNA<sub>Asp</sub>, p. 34 (humans) | Impacts coding potential of tRNA, protects tRNA from ribonuclease cleavage | UHPLC-MS/MS, LC-MC | T-cell lymphoma, colon cancer | [60–63]   |
| Modification                  | Code | Base | Domains | RNA Classes | Location and Frequency | Function                                                                 | Methods                          | Diseases                                    | Ref.        |
|------------------------------|------|------|---------|-------------|------------------------|--------------------------------------------------------------------------|----------------------------------|-------------------------------------------|------------|
| 5-methylcytidine             | m5C  | C    | All     | rRNA, tRNA, mRNA, eRNA, miRNA, IncRNA, viral RNA, vault RNA, snRNA, snoRNA | rRNA: m5C3761 and m5C4413 (well-conserved in eukaryotes); tRNA: variable loop, anticodon loop, and T stem; mRNA: enriched in 5'UTR | rRNA: ensures proper folding and translational fidelity; tRNA: ensures proper folding and stability, codon-anticodon interactions, and reading frame maintenance; mRNA: affects stability, translation rate; IncRNA: affects stability; vault RNA: required for biogenesis | m5C-RIP-seq, Aza-IP-seq, miCLIP-seq, TAWO-seq, RNA-BisSeq, RBS-seq, DR5, MeRIP-seq | ARID, D5, lactic acidosis, breast cancer, hypotonia / floppy baby syndrome, metabolism | [14,40,48,64–67] |
| 5-formylcytidine             | f5C  | C    | All     | tRNA, mt-tRNA | mt-tRNA<sub>Met</sub>, p.C34 (always) | Required for decoding of AUA codon in mitochondria | HPLC-MS | Breast cancer, systemic lupus erythematosus | [68,69] |
| 5-methyluridine              | m5U  | U    | All     | rRNA, tRNA | tRNA: p. 54 | Ensures fidelity of translation, folding, and stability of tRNA | FICC-Seq, iCLIP, miCLIP-seq | Breast cancer, systemic lupus erythematosus | [70–73] |
| 2′-O-methylation             | Nm   | All  | All     | rRNA, tRNA, mRNA, snoRNA, snoRNA | mRNA: 5'UTR, 3'UTR, CDS; tRNA: p. 4 | Nm increases the thermodynamic stability of RNA:RNA base pairs and stabilizes A-form RNA duplexes | RibomethSeq, 2D-TLC, Nm-seq, 2′OMe-seq, RTL-P, DRS, RibOxi-seq | Asthma, Alzheimer's disease | [48,74–79] |
| 1-methylguanosine            | m1G  | G    | All     | tRNA, mRNA | tRNA<sub>Leu</sub>, tRNA<sub>Pro</sub>, tRNA<sub>Arg</sub>, mRNA: p. 9 (always in S. cerevisiae); mRNA (0.00046% G in S. cerevisiae) | tRNA: prevents frameshifting; mRNA: reduces translation fidelity in a position- and codon-dependent manner | MR-FISH, LC-MS/MS, DRS | NA | [80–86] |
| 5-methylaminomethyl-2-thionouridine | mnm5s2U | U    | All     | tRNA | tRNA<sub>AAA</sub>, tRNA<sub>AAG</sub>, tRNA<sub>Lys3UUU</sub>: p. 37 (always) | Required for decoding of the lysine codons AAA and AAG by tRNA<sub>Lys3UUU</sub> | LC-MS/MS | NA | [87–89] |
| Wybutosine                   | yW   | G    | Archaea, eukaryotes | tRNA | tRNA<sup>P3</sup>: p. 37 (often) | Stabilizes codon-anticodon interactions | LC-MS/MS | NA | [90,91] |
| N4-acetylcytidine            | ac4C | C    | All     | tRNA, mRNA | tRNA: p. 12 (always); tRNA: in helix 34, 45; mRNA: enriched in 5'UTR and CDS (4250 sites in HeLa; not present in HEK293; 0.1% C in S. cerevisiae mRNA) | tRNA: increases translation efficiency and accuracy; mRNA: increases stability | acRIP-seq, ac4C-seq | NA | [92–95] |
| Modification                | Code | Base | Domains                           | RNA Classes | Location and Frequency                                                                 | Function                                                                 | Methods                                                                 | Diseases                                      | Ref.                        |
|----------------------------|------|------|-----------------------------------|-------------|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|---------------------------------------------|-----------------------------|
| 3-methylcytidine           | m3C  | C    | Eukaryotes                        | tRNA        | tRNA: p. 32 (30–90%, depending on tRNA)                                                   | Unknown                                                                 | AlkAniline-seq, HAC-seq, ARM-seq, DM-tRNA-seq, mim-tRNA-seq, hydro-tRNA-seq, LC-MS/MS, NAIL-MS | Several types of cancer                  | [57,96–101]                |
| Archaeosine                | G+   | G    | Archaea                           | tRNA        | tRNA: p. 15 (always), p.13 (in some species)                                             | Increases thermal stability of tRNA                                     | HPLC                                                                 | NA                                          | [102,103]                  |
| 5-methoxycarbonyl-methyl-2-thiouridine | mcm5s2U | U    | Eukaryotes                        | tRNA        | tRNA\[^{2\text{p}+}\], tRNA\[^{3\text{p}+}\], tRNA\[^{4\text{p}+}\], tRNA\[^{5\text{p}+}\], tRNA\[^{6\text{p}+}\], tRNA\[^{7\text{p}+}\], tRNA\[^{8\text{p}+}\] | Improves decoding efficiency of tRNA                                    | HPLC-MS                                                                | NA                                          | [88,104]                   |
| 2-thiocytidine             | s2C  | C    | Bacteria, eukaryotes              | tRNA        | tRNA\[^{2\text{p}+}\], tRNA\[^{3\text{p}+}\], tRNA\[^{4\text{p}+}\], tRNA\[^{5\text{p}+}\], tRNA\[^{6\text{p}+}\], tRNA\[^{7\text{p}+}\], tRNA\[^{8\text{p}+}\] | Restricts recognition of certain wobble codons                            | HPLC-MS                                                                | NA                                          | [105,106]                  |
| N2,N2-dimethyl-1guanosine  | m2,2G| G    | Archaea, eukaryotes               | tRNA, mRNA  | tRNA: p. 10, p. 26 (always); mRNA (0.00051% G in \textit{S. cerevisiae})               | tRNA: plays a role in tRNA folding and prevents tRNA from adopting wrong conformation; mRNA: reduces translation fidelity in a position- and codon-dependent manner | PhOxi-seq, LC-MS/MS                                                        | NA                                          | [82,107,108]                |
| N6-isopentenyl-adenosine   | i6A  | A    | Bacteria, eukaryotes              | tRNA        | tRNA\[^{2\text{p}+}\], tRNA\[^{3\text{p}+}\], tRNA\[^{4\text{p}+}\], tRNA\[^{5\text{p}+}\], tRNA\[^{6\text{p}+}\], tRNA\[^{7\text{p}+}\], tRNA\[^{8\text{p}+}\] | Increases translation fidelity and efficiency of cognate codons            | PHA6 assay, HPLC, Sanger                                                                 | NA                                          | [109–111]                  |
| N6-threo-1-carbamoyl-1-adenosine | t6A | A    | All                                | tRNA        | tRNA\[^{2\text{p}+}\], tRNA\[^{3\text{p}+}\], tRNA\[^{4\text{p}+}\], tRNA\[^{5\text{p}+}\], tRNA\[^{6\text{p}+}\], tRNA\[^{7\text{p}+}\], tRNA\[^{8\text{p}+}\] | Facilitates codon–anticodon pairing and prevents frameshift during protein synthesis | LC-MS/MS                                                                | MERFF, neurodegeneration, diabetes                             | [110–112]                  |
| 3-methyluridine            | m3U  | U    | All                                | rRNA, tRNA  | tRNA: U1498 (always in E. coli 16S); U2634 U2843 (in S. cerevisiae 25S); tRNA\[^{2\text{p}+}\], tRNA\[^{3\text{p}+}\], tRNA\[^{4\text{p}+}\], tRNA\[^{5\text{p}+}\], tRNA\[^{6\text{p}+}\], tRNA\[^{7\text{p}+}\], tRNA\[^{8\text{p}+}\] | Unknown                                                                 | MR-FISH, RP-HPLC                                                        | NA                                          | [85,113,114]                |
| Wyosine                    | imG  | G    | Archaea                           | tRNA        | tRNA\[^{2\text{p}+}\], tRNA\[^{3\text{p}+}\], tRNA\[^{4\text{p}+}\], tRNA\[^{5\text{p}+}\], tRNA\[^{6\text{p}+}\], tRNA\[^{7\text{p}+}\], tRNA\[^{8\text{p}+}\] | Stabilizes codon–anticodon interactions                                   | HPLC-MS                                                                | NA                                          | [115,116]                  |
| 1-methylinosine            | m1I  | I    | Bacteria, archaea, eukaryotes     | tRNA        | tRNA\[^{2\text{p}+}\], tRNA\[^{3\text{p}+}\], tRNA\[^{4\text{p}+}\], tRNA\[^{5\text{p}+}\], tRNA\[^{6\text{p}+}\], tRNA\[^{7\text{p}+}\], tRNA\[^{8\text{p}+}\] | Unknown                                                                 | LC-MS/MS                                                                | NA                                          | [83,117]                    |

NA—information not found; mRNA—messenger RNA; rRNA—ribosomal RNA; tRNA—transfer RNA; miRNA—microRNA; lncRNA—long noncoding RNA; snRNA—small nuclear RNA; snoRNA—small nucleolar RNA; eRNA—enhancer RNA; Mt-tRNA—mitochondrial tRNA; scRNA—small Cajal body-specific RNA; lincRNA—long intergenic noncoding RNA; 5′-UTR—5′-untranslated region; 3′-UTR—3′-untranslated region; CDS—coding sequence; FMN—flavin mononucleotide; Dus—dihydrouridine synthase; LC-MS/MS—liquid chromatography–mass spectrometry; RP-HPLC—reversed-phase liquid chromatography–tandem mass spectrometry; MeRIP-seq—methylated RNA immunoprecipitation sequencing; mCLIP—methylated individual-nucleotide-resolution crosslinking and immunoprecipitation; PA-m6A-seq—photo-crosslinking-assisted m6A sequencing; m6A-CLIP—m6A individual-nucleotide-resolution crosslinking and immunoprecipitation; DRS—direct RNA-seq; HCC—hepatocellular carcinoma; MERFF—myoclonic epilepsy with ragged red fibers; PAD—peripheral arterial disease; ARID—autosomal recessive forms of intellectual disabilities; DS—Dubowitz syndrome.
The majority of modifications from Table 1 can be found in transfer RNA, the most heavily modified class of RNA—each tRNA molecule on average has 13 modifications, many of which are required for proper codon decoding and robust translation [9]. Ribosomal RNA is also frequently modified, albeit to a lesser extent than tRNA [120]. Since tRNA and rRNA are the most abundant RNA classes, most known modifications were identified in them [121]. However, thanks to improvements in enrichment strategies and sequencing techniques, many of the modifications that were considered exclusive to rRNA and tRNA, as well as other new modifications, are now found in other RNA classes, including mRNA [122,123], miRNA [124], lncRNA [32], and even short-lived species such as eRNA [125].

In terms of importance, the selected modifications can be firstly classified as essential and nonessential. Essential modifications are shown to be necessary for important cellular processes, for example, translation, as is the case with dihydrouridine or 1-methylguanosine, for instance (see text below for all examples and details). Generally, a lack of these essential modifications significantly impairs cellular growth or causes death. We estimate that 10 modifications from our list (40%) represent essential modifications. It is possible that this percent is higher, since some of the nonessential modifications could have undiscovered essential roles. An additional indicator of the importance of a modification is its connection to human disease. Eleven of the modifications (44%) from our list are associated with various diseases, and nine of these (36%) are associated specifically with cancer. These results highlight the necessity of studying the epitranscriptome in detail, since RNA modifications are frequently essential for proper growth or linked to ailments of various natures.

As for the methods for the detection of RNA modifications, they are impressively numerous and range from polymerase chain reaction (PCR) and mass spectrometry to RNA sequencing and even fluorescence in situ hybridization (FISH). In the table, the most popular methods are given for each modification, but this is an extensive and complex topic that goes beyond the scope of this review. For excellent coverage of the range and specifics, as well as the technical challenges of the methods for the detection of RNA modifications, readers can refer to the review by Huang et al. [126].

4. RNA Modifications in Depth

Below, we describe the properties of several groups of biochemically and functionally related modifications, emphasizing the recent progress in establishing unique features that affect their distribution in RNA and their molecular function, as well as the specifics of the detection methods.

4.1. N6-methyladenosine (m6A)

N6-methyladenosine (m6A) is the most-studied modification in all life domains [21]. m6A is prevalent in eukaryotic RNA, especially within higher eukaryotic cells. m6A sites are present in mRNA, tRNA, rRNA, circRNA, miRNA, snRNA, and lncRNA [127]. The m6A modification is abundant in mRNA, and is essential for regulating RNA splicing, translation, stability, translocation, and the high-level structure [127,128].

In eukaryotes, the m6A modification is located in all mRNA regions: 5′UTR, CDS, and 3′UTR. The modification residues were enriched in 5′UTRs around the stop codons and in 3′UTRs adjacent to the stop codons. Approximately 35% of m6A residues are located within the CDS [129]. This modification is enriched not only in eukaryotes, e.g., in A. thaliana, but the m6A sites are also detected near the start codons [129]. The m6A peaks were frequently detected at miRNAs target sites [130].

N6-methyladenosine is installed by “writer” proteins, including METTL3, METTL14, METTL16, WTAP, KIAA1429, ZCCHC4, RBM15, ZC3H13, and ZCCHC4 [131,132]. In addition, the m6A reader proteins can recognize m6A-modified RNAs. The first group of proteins regulates the alternative splicing or processing of target transcripts and includes such enzymes as YTHDF1/2/3, YTHDC2, HNRNPC, and HNRNPA2B1 [133]. The second group includes eIF3 in eukaryotes and regulates protein expression [134]. The m6a mod-
4.2. Inosine (I) and 1-methylinosine (m1I)

Adenosine-to-inosine editing is a major pathway of RNA modifications that is present in all domains of life [140]. Inosine has different hybridization rules than adenosine; thus, A-to-I editing can affect the local RNA structure and the interactions with other RNA molecules and proteins [29]. Inosine is found in tRNA and mRNA as well as other noncoding RNA, such as miRNA [141].

In tRNA, the adenosine at position 34 (the first base of the anticodon) is frequently modified to inosine to support the mechanism of wobble codon recognition, since inosine can hybridize with adenosine, guanosine, and uridine [28]. This modification is absent in archaea and usually only found in tRNA^{Arg} in bacteria, while eukaryotes have seven or eight tRNAs modified in this way [142]. This modification is installed by the enzyme TadA in bacteria and adenosine deaminase acting on tRNA (ADAT) in eukaryotes [28]. Additionally, inosine has been discovered in positions 37 (the base directly adjacent to the anticodon) [143] and 57 (only in archaea) [144] in the form of 1-methylinosine, but the function of these modifications is not yet clear [117].

In mRNA, A-to-I editing changes the hybridization rules, since inosine is interpreted by tRNA and RNA-binding proteins (RBPs) as guanosine [145]. The mRNA editing in eukaryotes is performed by a family of enzymes called adenosine deaminases acting on RNA (ADARs), which are conserved across the Animalia kingdom [146]. Interestingly, the editing only occurs in double-stranded regions of mRNA and can affect the three-dimensional structure of the transcript [147]. In noncoding regions of mRNA, A-to-I editing can lead to an altered stability and localization of the transcripts [148]. In coding regions, A-to-I editing can change the codon identity, protein sequence, and function [145]. For instance, the glutamate receptor subunit GRIA2 has a transmembrane channel that can lose permeability to Ca^{2+} as a result of A-to-I editing in its coding region of mRNA [149]. Notably, A-to-I editing frequently affects brain-specific proteins [150].

Standard NGS protocols can reveal the locations of A-to-I editing, since inosine is interpreted as guanosine, and A-G genome mismatches arise in the final result [141]. Recently, a method to detect inosines in full-length transcripts using nanopore sequencing has been presented [33]. Additionally, adenosine-to-inosine RNA editing can be detected via LC-MS/MS with a high sensitivity [151,152].

The A-to-I editing mechanism has been repurposed in the last three years to introduce precise changes to specific mRNAs by a complex of ADAR and RNA-targeting catalytically dead Cas nucleases [153]. This could lead to new effective therapy options for multiple severe disorders [154].

4.3. Pseudouridine (Ψ)

Pseudouridine (Ψ) was the first modified ribonucleoside discovered in 1951 [155] and is the most abundant post-transcriptionally modified nucleotide in RNA from all three domains of life [34]. It is detected in a wide range of RNA, from tRNA and rRNA to various snRNAs [34]. In tRNA, Ψ is detected at position 55 and is associated with stress resistance [156]. In E. coli, this modification is catalyzed by the truB gene [157]. In archaeal tRNA, it is installed by Cbf5 and Pus10 [158], and in Eukaryota, it is installed by Pus4 [159].
Pseudouridylation also increases the stability of tRNA [160]. In rRNA, the Ψ sites are crucial for ribosome assembly and protein synthesis [161].

Uridine is transformed into Ψ by a class of enzymes known as pseudouridine synthases. For each species, these enzymes are different. For instance, in humans, Ψ is installed by a methyltransferase complex, including RPUSD1/2/3/4, PUS10, PUS7L, and TRUB2, while in yeast, this complex includes PUS2/5/6/8/9 enzymes. Both species have similar pseudouridine synthases, for example, PUS1/4 and DKC1 [34]. Pseudouridylation is irreversible due to the conversion from U to Ψ, as the C-N glycosidic bond of U is isomerized to a much more inert C-C bond in Ψ. This modification can be detected by multiple NGS protocols, such as Pseudo-Seq [36], PSI-seq [37], CeU-Seq [38], Ψ-Seq [39], and RBS-seq [40]. Pseudouridylation has been implicated in various human diseases, including multiple primary cancers [35,162], mitochondrial myopathy, sideroblastic anemia [163], and dyskeratosis congenita [41].

4.4. 5-methyluridine (m5U)

The next uridine modification is 5-methyluridine (m5U), having a single methyl substituent at the 5-position on the uracil ring. It is frequently found in bacterial and eukaryotic tRNAs at position 54 in the T loop [73]. m5U sites were recently detected in human mitochondrial tRNAs. The 5-methyluridine modification is also found in rRNA, such as the 23S rRNA at positions U747 and U1939 in B. subtilis [164,165]. The modification increases the fidelity and efficiency of protein synthesis by stabilizing the three-dimensional structure of tRNA in vitro [166]. Experimental methods such as FICC-Seq [70], miCLIP-seq, and iCLIP [71] can be used for m5U detection.

In E. coli and S. cerevisiae, 5-methyluridine formation is catalyzed by various types of enzymes such as TrmA [167] and Trm2p [168]. In mammalian cells, m5U is produced by the TRMT2A and TRMT2B enzymes [169]. This modification is associated with breast cancer [166] and systemic lupus erythematosus [72].

4.5. 2′-O-methylation of ribose (Nm or 2′-O-Me)

In short, 2′-O-methyl ribose is Nm, where N stands for any nucleotide. Such a modification can occur on any base by adding a methyl group (-CH3) to the 2′-hydroxyl (-OH) of the ribose moiety. Nm modifications (Am, Gm, Um, and Cm) are found in multiple types of RNA, such as snRNA, snoRNA, lncRNA, rRNA, tRNA, and mRNA [170]. 2′-O-methylation is frequently located at position four in tRNA [171], but most commonly at position seven in eukaryotes and positions 4, 18, 32, 34, 44, and 54 in bacteria. Positions 4, 18, 32, 34, and 44 are found in S. cerevisiae [172]. The modification occurs on the 5′ and 3′ UTRs in mRNA and also on AGUA-motif in CDS [77]. Such a modification has the potential to influence the RNA structure, stability, and interactions. For instance, it can disrupt RNA tertiary structures. The modification plays a role in epigenetic gene regulation [74].

The Nm modification is produced by fibrillarin in eukaryotes and their homolog Nop1 in yeast [173]. Different enzymes produce the Nm modification for different species and nucleotides. For example, in yeast, the Am modification is catalyzed by the Nop and Trm13 enzymes. In addition, this modification is produced in Streptomyces actoaus by Nsr [174]. Cm is catalyzed by Trm13, Nop1, and Trm7 in yeast and RlmM and RsmI in E. coli [175].

The modification can be detected by various methods, from liquid chromatography coupled with LC/MS and two-dimensional thin-layer chromatography (2D-TLC) to high-throughput sequencing (Table 1) [76,77,79].

2′-O-methylation is involved in multiple human diseases, such as Prader–Willi syndrome, asthma, Alzheimer’s disease [74], and breast cancer [176].

4.6. 1-methyladenosine (m1A)

As another modification that involves the methylation of adenosine, in this case at N1, 1-methyladenosine is known to play an essential structural role in tRNA and rRNA in
all organisms [177]. The presence and relevance of m1A in other RNA classes, primarily mRNA, is under serious doubt despite initial findings (see below).

In tRNA, m1A has been identified at a total of six positions, one of which, m1A58, is conserved across all three domains of life [178]. Other positions are less universal and are often domain-specific or found only in mitochondrial tRNA [178]. In humans, the m1A58 modification of cytosolic tRNA is installed by the heterotetramer complex TRM6-TRM61A, and a knockdown of these proteins is detrimental to the growth of human cells [179]. This is explained by the critical role of m1A58 in the stabilization and maturation of eukaryotic initiator-tRNA\textsubscript{Met} [6]. In other tRNAs, m1A58 can be present at various levels and can even be demethylated by the protein ALKBH1, which, however, can lead to a decreased usage of the tRNA [180]. Interestingly, increased expression and activity of TRM6-TRM61A complex are associated with the progression of hepatocellular carcinoma [54]. Another location of 1-methyladenosine in tRNA at position nine is commonly observed in animal mt-tRNA, where a TRM61B enzyme installs it. At this position, m1A is essential because it is required for the correct folding of mt-tRNA [181].

N1-methyladenosine is structurally vital in ribosomal RNA [177]. In the 28S rRNA in human cells, m1A1322 is installed by the protein nucleomethylin (NLM), and this position is conserved in yeast and \textit{C. elegans} [182]. The loss of NLM leads to the impaired folding of the large ribosomal subunit and causes p53-dependent cell death in humans [183], as well as significantly decreased viability in mice [184].

As for mRNA, two initial studies utilizing an enrichment strategy with an m1A-specific antibody and subsequent RNA-sequencing identified large numbers (1000 for m(1)A-ID-seq [185] and 7000 for m1A-seq [59]) of m1A sites in human mRNA, located primarily in 5’UTR. However, subsequent studies utilizing more precise methods such as m1A-seq-TGIRT [58] and m1A-MAP [186] detected significantly fewer high-confidence sites of m1A in mRNA. The reanalysis of the two initial studies revealed that most of the identified sites were due to the cross-reactivity of the antibody used for the IP experiments [187]. Therefore, while a m1A modification can, in principle, occur in mRNA, its frequency and stoichiometry are low, and its role remains to be further investigated.

4.7. Dihydrouridine

Until recently, dihydrouridine (D) was found only in transfer RNA, located in the appropriately named D loop, and very seldom in prokaryotic rRNA [49]. However, several articles published last year reported dihydrouridine’s occurrence in mRNA, IncRNA, and snoRNA, providing evidence for its physiological importance (see below).

In tRNA, dihydrouridine is found at positions 16, 17, 20, 20a, 20b, and 47, although the specific positions may vary from species to species [188]. Positions 16 and 20, located in the T loop of transfer RNA, are the most frequently edited since dihydrouridine at these positions is essential for the correct folding of tRNA [189]. In humans, dihydrouridine is installed by dihydrouridine synthases 1–3 (DUS1-3) [49], whose altered expression has been implicated in the progression of non-small-cell lung carcinomas (NSCLC) [190].

Two recently developed NGS-based methods have revealed the existence of dihydrouridine in the mRNA, IncRNA, and snoRNA of yeast and human cells. The first method, Rho-seq, utilizes rhodamine labeling to detect dihydrouridine transcriptome-wide [52]. Besides the established positions of D in tRNA, this method led to the identification of 143 dihydrouridine sites in \textit{S. pombe}, which were spread across 125 protein-coding genes and one IncRNA. It is reported that the modification of tubulin mRNA is essential for proper meiotic chromosome segregation and gamete viability. D-seq, another method developed to uncover the distribution of dihydrouridine in the transcriptome, was used to identify 48 novel D sites in 23 different snoRNAs and 130 sites in 112 mRNAs of \textit{S. cerevisiae} [51]. Together, these results show that dihydrouridine is present in more RNA classes than originally thought and has important biological roles.
4.8. N4-acetylcytidine (ac4C)

N4-acetylcytidine (ac4C) is one of the most-studied modifications of tRNA and rRNA and is found in all domains of life [92]. A recent study also illustrated that this modification is detected in mRNA [94]. N4-acetylcytidine was found in position 12 of the yeast leucine tRNA (tRNA\textsubscript{Leu}) [191] and the brewer’s yeast serine tRNAs (tRNA\textsubscript{Ser}) [192]. This modification maintains the stability of tRNA\textsubscript{Ser} and helps to increase the high fidelity of protein translation [193]. In human and yeast rRNA, the ac4C sites were detected in helices 34 and 45 [92]. These positions are essential for maintaining the accuracy of protein translation [194]. In mRNA, ac4C is enriched in the CDS and 5′ UTR [94]. N4-acetylcytidine increases mRNA stability and protein translation efficiency [195]. Remarkably, the ac4C sites are absent in the mRNA from HEK293 cells [93], but present, for instance, in human HeLa cells [94].

N-acetyltransferase 10 (NAT10), a member of the GCN5-related NAT (GNAT) family of histone acetyltransferases, catalyzes the formation of ac4C on rRNA, tRNA, and mRNA [196]. Additionally, the formation of ac4C occurs with the help of the ribosomal RNA cytidine acetyltransferase 1 (Rra1) in rRNA, tRNA, and mRNA [94,95]. The tRNA acetyltransferase (TAN1) also plays an important role in the formation of ac4C on tRNA\textsubscript{Leu} and tRNA\textsubscript{Ser} in \textit{S. cerevisiae} [197].

Nowadays, ac4C can be detected by various methods, including LC-MS/MS [198] and acRIP-seq [199].

4.9. Methyluridine (m3U)

3-Methyluridine (m3U, N3-Methyluridine) can be detected in the 23S rRNA of archaea; 16S and 23S rRNA of eubacteria [114]; and 18S, 25S, and 28S rRNA of eukaryotes [113]. The 28S rRNA contains this modification at position 4513 [114] and the 16S rRNA of \textit{E. coli} contains it at position U1498 [200]. The yeast 25S rRNA contains two m3U residues at positions 2634 and 2843. These modifications are located in domain V of the 25S rRNA, and are responsible for the catalytic function of the ribosome [201]. The Bmt5 (Yil096c) and Bmt5 (Ylr063w) enzymes are responsible for the methylation of uridine residues in positions U2634 and U2843. This modification can be detected by reversed-phase high-performance liquid chromatography (RP-HPLC) [114].

Methylation-sensitive RNA fluorescence can detect m3U in situ hybridization (MR-FISH), which is sensitive to single methylations, and can characterize the composition of heterogeneous mixtures of cells that differ only in their RNA methylation [85]. In addition, this modification can be detected by reverse-phase high-performance liquid chromatography (RP-HPLC) [114].

4.10. 5-methylcytidine (m5C) and 5-formylcytidine (f5C)

The methylation of the cytosine C5 atom has been identified in all three domains of life and many RNA types—aside from tRNA, rRNA, and mRNA, m5C is present in many classes of other noncoding RNAs [206]. In rRNA, m5C is found in small numbers that differ from one species to another [207]. For instance, \textit{E. coli} rRNA only contains three m5C residues, while \textit{T. thermophilus} has five or six [207]. In human cells, the 28S rRNA contains two m5C sites, m5C3761 and m5C4413, and it is reported that they are indispensable for the stable folding of rRNA and ensuring translational fidelity [208]. These sites are well-conserved in eukaryotes [209].

m5C has also been identified in tRNA, where it is usually located at several positions in the variable loop, anticodon loop, and T stem [189]. Two enzymes, NSUN2 and TRMDT1, are responsible for installing this modification in different subsets of tRNA in humans [210]. In these positions, 5-methylcytidine is believed to ensure proper tRNA folding and stability,
codon–anticodon interactions, and the maintenance of the reading frame [211]. In several tRNAs, for example, in human mt-tRNA\textsubscript{Met}, C34 is modified to 5-methylcytidine and subsequently to 5-formylcytidine, which is required for the proper decoding of the AUA codon in mitochondria [68]. The insufficient NSUN2-mediated deposition of methyl groups on the cytidines in tRNA has been linked to neurodevelopmental disorders and oncogenesis [15,212]. Remarkably, some of the less crucial m5C sites in tRNA can be written/erased dynamically, conferring tolerance to various toxic exposures [13].

While the existence of 5-methylcytidine in mRNA has been known for the last 60 years, the distribution frequency and the exact locations of this modification have remained largely unknown until the last decade, when a variety of NGS-based methods were developed for this task [213]. m5C has been shown to be present in bacterial, archaeal, and eukaryotic mRNA [214]. However, the initial studies investigating the locations of m5C modifications in mRNA have produced different and somewhat controversial results regarding the frequency of this modification, with the total number of identified sites varying from 745 [121] to more than 10,000 [210]. Recently, an improved technique based on bisulfite sequencing was applied to discover m5C locations in human and mouse mRNA, resulting in the identification of a total of 3212 and 2498 high-confidence sites, respectively, with the highest density of m5C observed in the 5′UTR [215]. In mRNA, 5-methylcytidine has been shown to affect its stability [65], translation rate [216], and potential to form double-stranded structures [217].

The m5C modification has also been found in other classes of RNA, such as lncRNA, where it can increase its stability [218]; vault RNA, where it is required for its biogenesis [219]; and other noncoding RNA [220].

4.11. 7-methylguanosine (m7G)

7-methylguanosine is a common and well-known RNA modification found in all studied organisms [42]. Its recognition is associated mainly with its role as a part of the eukaryotic mRNA cap structure, a prominent feature of eukaryotic mRNA required for the proper translation and evasion from the innate immune system [221]. However, here we would like to focus on the roles of internal m7G modification.

Internal m7G has been detected in rRNA, tRNA, mRNA, and miRNA [42,43]. Ribosomal RNA from bacteria and eukaryotes contains several 7-methylguanosines [46]. In humans, SSU rRNA is methylated at position G1639, and this modification is conserved in yeast [222]. However, the methylation of this position by methyltransferase METTL2 is apparently not vital [222]. In contrast, at position 46 in the variable region of tRNA, m7G is present almost universally across all domains of life, and its biogenetic, structural, and functional properties have been described in greater detail [42].

Several high-throughput methods aimed at detecting m7G modifications with a single-base resolution have been recently proposed. The first method, m7G-meRIP-seq, resulted in the detection of 3823 m7G peaks in mRNA shared between three human cell lines [44]. Shortly thereafter, the m7G miCLIP-seq method was utilized to detect m7G sites in the HeLa and Hek293 cell lines [45]. The identified number of m7G locations (2896 internal m7G clusters within 1635 mRNAs in HeLa cells and 4522 clusters within 2318 mRNAs in 293T cells) was similar to a previous study, although there were differences in the exact positions of m7G in transcripts between the studies. Remarkably, the m7G modification has been shown to be dynamic, and its function has been linked to the regulation of translation [45].

The question of whether m7G exists in other classes of RNA remains controversial. Borohydride reduction sequencing (BoRed-seq) has been used to show that miRNA let-7 is methylated by METTL1 and the installed 7-methylguanosine is vital for the biogenesis of this miRNA. However, these findings have been disputed [223], and although the authors of the original study responded to the criticism [224], another study utilizing a different method termed m7G mutational profiling sequencing (m7G-MaP-seq) also failed to detect any m7G sites in human miRNA as well as snRNA and snoRNA [46].
4.12. tRNA Structural Modifications

The largest fraction of RNA modifications in our selection were primarily implicated in structural roles in tRNA, where they maintained the correct folding and stability of the transfer RNA molecules and the desired parameters of the codon–anticodon interactions [225].

Modifications of tRNA in the anticodon region, primarily in position 34, are widespread because they are responsible for the mechanism of wobble base pairing, which allows one tRNA to recognize multiple mRNA codons, thus reducing the overall number of tRNAs required for translation [226]. For example, 5-methylaminomethyl-2-thiouridine (mnm5s2U) at this position is required for the proper decoding of the lysine-encoding codons AAA and AAG by tRNA\textsuperscript{Lys3}, while another uridine modification, 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U), is essential for the proper decoding of NNR codons [88].

Bases adjacent to the anticodon are also frequently modified to alter the specific parameters of translation. Two modified adenosines, N6-isopentenyladenosine (i6A) and N6-threonylcarbamoyladenosine (t6A) found in position 37 directly adjacent to the anticodon, positively affected the translation efficiency and prevented frameshifting [111,112]. Another modification of the 37th residue, 1-methylguanosine, is always present in a subset of tRNA in all domains of life and has a critical function to prevent frameshifting [80].

Wyosine and its related modification wybutosine are complex modifications to guanosine that are synthesized by a group of enzymes [115]. They are found at position 37 in tRNA\textsuperscript{Arg} ubiquitously in archaea and eukaryotes, and they ensure effective codon recognition by stabilizing the codon–anticodon interactions during decoding on the ribosome [90]. Interestingly, some modifications in this region can restrict the recognition of certain wobble codons; for instance, this is the role of 2-thiocytidine (s2C) at position 32 in bacterial and archaeal tRNA\textsuperscript{Arg} and tRNA\textsuperscript{Ser2} [106]. This demonstrates the complicated functional interplay between modifications of tRNA, of which there are other examples [225]. The 32nd residue in tRNA is subject to another frequent modification in eukaryotic cells, 3-methylcytosine. While the exact function of this modification is not yet known, its disruption has been associated with impaired cellular growth and oncogenesis [96].

Another set of modifications affects other regions of tRNA and usually performs structural functions. N2,N2-dimethylguanosine, which is almost always present in positions 10 and 26 of tRNA in archaea and eukaryotes, plays an essential role in the correct folding of tRNA [108]. Only one modification in our list is exclusive to archaea, and is suitably named archaeosine [102]. This modification is always found at position 15 and seldom in position 13 [103]. So far, the only known function of archaeosine in tRNA is its ability to increase the molecule’s thermostability, which may be especially important to archaea since many archaeal species are thermophiles [103].

Several modifications thought to be exclusive to tRNA were discovered in other RNA types, most notably mRNA. For instance, 1-methylguanosine and N2,N2-dimethylguanosine were identified in \textit{S. cerevisiae} mRNA in small quantities using LC/MS-MS and were also shown to affect the translation efficiency in a position-specific manner [82]. However, further studies are required to confirm these results.

5. Conclusions and Perspectives

In recent years, there has been an increased interest in the epitranscriptome. Among the existing RNA modifications, currently numbering ~300 variants, special attention has been focused on a few of them, such as m6A, I, \(\Psi\), m7G, and Nm. This is caused by their high frequency of occurrence in all domains and sequences, a wide range of functions performed, and several options for relatively simple detection methods.

Most RNA modifications are found in tRNA, and LC-MS/MS-based approaches are used for their detection. Sequencing-based methods are utilized mostly to detect modifications in other types of RNA molecules, in particular mRNA. Nowadays, protocols have been developed for processing data obtained using both nanopore-based long-read sequencing (direct RNA-seq) and more traditional short-read technology (RNA-seq).
The gap in the popularity of research on epitranscriptomic events is significant. Our analysis of epitranscriptome studies revealed that other modifications are mentioned in less than 20% of articles compared with the ubiquitous top five modifications (Table S1). This bias does not provide an opportunity to look extensively at the functions performed by the epitranscriptome. However, by discussing the currently known information about other modifications in the same context and in an equal manner, we illustrated the integrated complexity and interconnectedness of the epitranscriptome, therefore improving the recognition of less-studied modifications. This will hopefully lead to more active research efforts to investigate their properties in full detail.

Although their function is still unknown for most RNA modifications, it has been shown that in some cases, they play a key role in the development of a number of diseases and can be used as therapeutic targets. In particular, the study of the epitranscriptome initiated the development of mRNA vaccines. Although the first attempts did not reach the clinic, eventually, COVID-19 mRNA vaccines showed their high efficiency in preventing severe disease [227–229]. Such a success will stimulate interest in the development of RNA-based drugs. In addition, RNA modification modulators may serve as potential therapeutic targets for cancer. Nowadays, epitranscriptomic drugs have shown potential to promote the efficacy of chemotherapy in preclinical studies, and clinical trials should be designed and conducted in the future [230,231].

All of the above would have been impossible without the development of NGS technology, enabling it to detect modifications with a resolution of up to one nucleotide. However, not all RNA modifications can be detected by NGS-based methods, e.g., m3U and Q. The development of new experimental and bioinformatics methods will expand the list of modifications—“favorites”, paving the road for novel epitranscriptomic biomarkers, drugs, and vaccines.

In conclusion, we believe that the present review will improve the recognition of the lesser-known modifications, many of which are currently being found in additional classes of RNA and have already been shown to perform important biological functions. Considering the increasing evidence of the dynamic and interconnected behavior and regulation of these modifications, it is essential to investigate the full functional capacity of all, not just most, prevalent RNA modifications to comprehensively understand the epitranscriptome. Furthermore, the integration of the known information regarding specific properties of certain RNA modifications can lead to improved and more universal methods for their detection.

Supplementary Materials: The supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms232213851/s1.

Author Contributions: Conceptualization, V.A.A., G.V.D. and E.V.P.; methodology, V.A.A. and G.V.D.; formal analysis, G.V.D.; writing—original draft preparation, V.A.A. and G.V.D.; writing—review and editing, I.Y.K., O.I.K. and E.V.P.; visualization, V.A.A., G.V.D. and E.V.P.; supervision, O.I.K. and E.V.P.; project administration, E.V.P.; funding acquisition, E.V.P. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by the Ministry of Education and Science of the Russian Federation, grant number 075-15-2021-933 (“Avogadro” large-scale research facilities, unique project ID: RF00121X0004).

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Davis, F.F.; Allen, F.W. Ribonucleic Acids from Yeast Which Contain a Fifth Nucleotide. J. Biol. Chem. 1957, 227, 907–915. [CrossRef]
2. Grosjean, H. RNA Modification: The Golden Period 1995–2015. RNA 2015, 21, 625–626. [CrossRef] [PubMed]
3. Frye, M.; Jaffrey, S.R.; Pan, T.; Rechavi, G.; Suzuki, T. RNA Modifications: What Have We Learned and Where Are We Headed? Nat. Rev. Genet. 2016, 17, 365–372. [CrossRef] [PubMed]
4. Boccaletto, P.; Stefaniak, F.; Ray, A.; Cappannini, A.; Mukherjee, S.; Purta, E.; Kurkowski, M.; Shirvanzadeh, N.; Destefanis, E.; Groza, P.; et al. MODOMICS: A Database of RNA Modification Pathways. 2021 Update. **Nucleic Acids Res.** 2022, 50, D231–D235. [CrossRef]

5. Roundtree, I.A.; Evans, M.E.; Pan, T.; He, C. Dynamic RNA Modifications in Gene Expression Regulation. **Cell** 2017, 169, 1187–1200. [CrossRef]

6. Anderson, J.; Phan, L.; Cuesta, R.; Carlson, B.A.; Pak, M.; Asano, K.; Björk, G.R.; Tamame, M.; Hinnebusch, A.G. The Essential Gcd10p-Gcd14p Nuclear Complex Is Required for 1-Methyladenosine Modification and Maturation of Initiator Methionyl-tRNA. **Genes Dev.** 1998, 12, 3650–3662. [CrossRef] [PubMed]

7. Deng, S.; Zhang, J.; Su, J.; Zuo, Z.; Zeng, L.; Liu, K.; Zheng, Y.; Huang, X.; Bai, R.; Zhuang, L.; et al. RNA M6A Regulates Transcription via DNA Demethylation and Chromatin Accessibility. **Nat. Genet.** 2022, 54, 1427–1437. [CrossRef]

8. Zhou, K.I.; Shi, H.; Lyu, R.; Wylder, A.C.; Matuszek, Z.; Pan, J.N.; He, C.; Parisien, M.; Pan, T. Regulation of Co-Transcriptional Pre-mRNA Splicing by M6A through the Low-Complexity Protein HnRNPQ. **Mol. Cell** 2019, 76, 70–81.e9. [CrossRef]

9. Jackman, J.E.; Alfonzo, J.D. Transfer RNA Modifications: Nature’s Combinatorial Chemistry Playground. Wiley Interdiscip. Rev. **RNA** 2013, 4, 35–48. [CrossRef]

10. Wang, T.; Li, X.; Zhang, X.; Wang, Q.; Liu, W.; Lu, X.; Gao, S.; Liu, Z.; Liu, M.; Gao, L.; et al. RNA Motifs and Modification Involve in RNA Long-Distance Transport in Plants. **Front. Cell Dev. Biol.** 2021, 9, 651276. [CrossRef]

11. Tong, J.; Zhang, W.; Chen, Y.; Yuan, Q.; Qin, N.-N.; Qu, G. The Emerging Role of RNA Modifications in the Regulation of Antiviral Innate Immunity. **Front. Microbiol.** 2022, 13, 846525. [CrossRef] [PubMed]

12. Zhou, J.; Wan, J.; Gao, X.; Zhang, X.; Jaffrey, S.R.; Qian, S.-B. Dynamic m(6)A MRNA Methylation Directs Translational Control of Heat Shock Response. **Nature** 2015, 526, 591–594. [CrossRef] [PubMed]

13. Chan, C.T.Y.; Dyavahla, M.; DeMott, M.S.; Taghibazadeh, K.; Dedon, P.C.; Begley, T.J. A Quantitative Systems Approach Reveals Dynamic Control of TRNA Modifications during Cellular Stress. **PLoS Genet.** 2010, 6, e1001247. [CrossRef]

14. Jonkhout, N.; Tran, J.; Smith, M.A.; Schonrock, N.; Mattick, J.S.; Novoza, E.M. The RNA Modification Landscape in Human Disease. **RNA** 2017, 23, 1754–1769. [CrossRef] [PubMed]

15. Delaunay, N.; Frye, M. RNA Modifications Regulating Cell Fate in Cancer. **Nat. Cell Biol.** 2019, 21, 552–559. [CrossRef]

16. Feng, Q.; Wang, D.; Xue, T.; Lin, C.; Gao, Y.; Sun, L.; Jin, Y.; Liu, D. The Role of RNA Modification in Hepatocellular Carcinoma. **Front. Pharmacol.** 2022, 13, 984453. [CrossRef]

17. Esteve-Puig, R.; Climent, F.; Piñeiro, D.; Domingo-Domènech, E.; Davalos, V.; Encuentra, M.; Rea, A.; Espejo-Herrera, N.; Soler, M.; Lopez, M.; et al. Epigenetic Loss of M1A RNA Demethylase ALKBH3 in Hodgkin Lymphoma Targets Collagen, Conferring Poor Clinical Outcome. **Blood** 2021, 137, 994–999. [CrossRef]

18. Barbieri, I.; Kouzarides, T. Role of RNA Modifications in Cancer. **Nat. Rev. Cancer** 2020, 20, 303–322. [CrossRef]

19. Nance, K.D.; Meier, J.L. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines. **ACS Cent. Sci.** 2021, 7, 748–756. [CrossRef]

20. Ule, J.; Hwang, H.-W.; Darnell, R.B. The Future of Cross-Linking and Immunoprecipitation (CLIP). **Cold Spring Harb. Perspect. Biol.** 2018, 10, a032243. [CrossRef]

21. Zou, S.; Toh, J.D.W.; Kong, K.H.Q.; Gao, Y.-G.; Hong, W.; Woon, E.C.Y. N(6)-Methyladenosine: A Conformational Marker That Regulates the Substrate Specificity of Human Demethylases FTO and ALKBH5. **Sci. Rep.** 2016, 6, 25677. [CrossRef] [PubMed]

22. Oerum, S.; Meynier, V.; Catala, M.; Tisné, C. A Comprehensive Review of M6A/M6Am RNA Methyltransferase Structures. **Nucleic Acids Res.** 2021, 49, 7239–7255. [CrossRef] [PubMed]

23. Lorenz, D.A.; Sathe, S.; Einstein, J.M.; Yeo, G.W. Direct RNA Sequencing Enables M6A Detection in Endogenous Transcript Isoforms at Base-Specific Resolution. **RNA** 2020, 26, 19–28. [CrossRef]

24. Jia, G.; Fu, Y.; Zhao, X.; Dai, Q.; Zheng, G.; Yang, Y.; Yi, C.; Lindahl, T.; Pan, T.; Yang, Y.-G.; et al. N6-Methyladenosine in Nuclear RNA Is a Major Substrate of the Obesity-Associated FTO. **Nat. Chem. Biol.** 2011, 7, 885–887. [CrossRef] [PubMed]

25. Antanaviciute, A.; Baquero-Perez, B.; Watson, C.M.; Harrison, S.M.; Lascelles, C.; Crininn, L.; Markham, A.F.; Bonthorn, D.T.; Whitehouse, A.; Carr, I.M. M6AViewer: Software for the Detection, Analysis, and Visualization of N6-Methyladenosine Peaks from M6A-Seq/ME-RIP Sequencing Data. **RNA** 2017, 23, 1493–1501. [CrossRef]

26. Yang, C.; Hu, Y.; Zhou, B.; Bao, Y.; Li, Z.; Gong, C.; Yang, H.; Wang, S.; Xiao, Y. The Role of M6A Modification in Physiology and Disease. **Cell Death Dis.** 2020, 11, 1–16. [CrossRef] [PubMed]

27. Cao, G.; Li, H.-B.; Yin, Z.; Flavell, R.A. Recent Advances in Dynamic M6A RNA Modification. **Open Biol.** 2016, 6, 160003. [CrossRef]

28. Torres, A.G.; Piñeiro, D.; Filonava, L.; Stracker, T.H.; Batlle, E.; Ribas de Pouplana, L. A-to-I Editing on TRNAs: Biochemical, Biological and Evolutionary Implications. **FEBS Lett.** 2014, 588, 4279–4286. [CrossRef]

29. Srinivasan, S.; Torres, A.G.; Ribas de Pouplana, L. Inosine in Biology and Disease. **Genes** 2021, 12, 600. [CrossRef]

30. Paul, M.S.; Bass, B.L. Inosine Exists in MRNA at Tissue-Specific Levels and Is Most Abundant in Brain MRNA. **EMBO J.** 1998, 17, 1120–1127. [CrossRef]

31. Torres, A.G.; Piñeiro, D.; Rodríguez-Escribiá, M.; Camacho, N.; Reina, O.; Saint-Léger, A.; Filonava, L.; Batlle, E.; Ribas de Pouplana, L. Inosine Modifications in Human TRNAS Are Incorporated at the Precursor TRNA Level. **Nucleic Acids Res.** 2015, 43, 5145–5157. [CrossRef]
32. Torsin, L.I.; Petrescu, G.E.D.; Sabo, A.A.; Chen, B.; Brehar, F.M.; Dragomir, M.P.; Calin, G.A. Editing and Chemical Modifications on Non-Coding RNAs in Cancer: A New Tale with Clinical Significance. *Int. J. Mol. Sci.* 2021, 22, 581. [CrossRef] [PubMed]

33. Nguyen, T.A.; Heng, J.W.J.; Kaewsapsak, P.; Kok, E.P.L.; Stanojević, D.; Liu, H.; Cardilla, A.; Praditya, A.; Yi, Z.; Lin, M.; et al. Direct Identification of A-to-I Editing Sites with Nanopore Native RNA Sequencing. *Nat. Methods* 2022, 19, 833–844. [CrossRef] [PubMed]

34. Penzo, M.; Guerrieri, A.N.; Zacchini, F.; Terret, D.; Montanaro, L. RNA Pseudouridylation in Physiology and Medicine: For Better and for Worse. *Genes* 2017, 8, 301. [CrossRef] [PubMed]

35. Estève-Puig, R.; Bueno-Castañon, A.; Esteller, M. Writers, Readers and Erasers of RNA Modifications in Cancer. *Cancer Lett.* 2020, 474, 127–137. [CrossRef]

36. Carlile, T.M.; Rojas-Duran, M.F.; Gilbert, W.V. Pseudo-Seq: Genome-Wide Detection of Pseudouridine Modifications in RNA. *Methods Enzymol.* 2015, 560, 219–245. [CrossRef] [PubMed]

37. Lovejoy, A.F.; Riordan, D.P.; Brown, P.O. Transcriptome-Wide Mapping of Pseudouridines: Pseudouridine Synthases Modify Specific MRNAs in *S. cerevisiae*. *PLoS ONE* 2014, 9, e110799. [CrossRef] [PubMed]

38. Li, X.; Zhu, P.; Ma, S.; Song, J.; Bai, J.; Sun, F.; Yi, Z.; Lin, M.; et al. Chemical Pulldown Reveals Dynamic Pseudouridylation of the Mammalian Transcriptome. *Nat. Chem. Biol.* 2015, 11, 592–597. [CrossRef] [PubMed]

39. Schwartz, S.; Bernstein, D.A.; Mumbach, M.R.; Jovanovic, M.; Herbst, R.H.; Lehnardt, S.; Guttmann, M.; Sättijä, R.; Lander, E.S.; et al. Transcriptome-Wide Mapping Reveals Widespread Dynamic-Regulated Pseudouridylation of ncRNA and MRNA. *Cell* 2014, 159, 148–162. [CrossRef]

40. Khoddami, V.; Yerra, A.; Mosbruger, T.L.; Fleming, A.; Burrows, C.; Cairns, B.R. Transcriptome-Wide Profiling of Multiple RNA Modifications Simultaneously at Single-Base Resolution. *Proc. Natl. Acad. Sci. USA* 2019, 116, 6784–6789. [CrossRef]

41. Garus, A.; Autexier, C. Dyskerin: An Essential Pseudouridine Synthase with Multifaceted Roles in Ribosome Biogenesis, Splicing, and Telomere Maintenance. *RNA* 2021, 27, 1441–1458. [CrossRef]

42. Ueda, Y.; Ooshio, I.; Fusamia, Y.; Kitae, K.; Kawaguchi, M.; Jingushi, K.; Hase, H.; Harada, K.; Hirata, K.; Tsujikawa, K. AlkB Homolog 3-Mediated TRNA Demethylation Promotes Protein Synthesis in Cancer Cells. *Sci. Rep.* 2017, 7, 42271. [CrossRef]

43. Kasprzak, J.M.; Czerwoniec, A.; Bujnicki, J.M. Molecular Evolution of Dihydrouridine Synthases. *Nucleic Acids Res.* 2019, 47, e126. [CrossRef]

44. Zhang, L.-S.; Liu, C.; Ma, H.; Dai, Q.; Sun, H.-L.; Luo, G.; Zhang, Z.; Zhang, L.; Hu, L.; Dong, X.; et al. Transcriptome-Wide Mapping of Internal N7-Methylguanosine Methylyme in Mammalian MRNA. *Mol. Cell* 2019, 74, 1304–1316.e8. [CrossRef]

45. Malbec, L.; Zhang, T.; Chen, Y.-S.; Zhang, Y.; Sun, B.-F.; Shi, B.-Y.; Zhao, Y.-L.; Yang, Y.; Yang, Y.-G. Dynamic Methylyme of Internal MRNA N7-Methylguanosine and Its Regulatory Role in Translation. *Cell Res.* 2019, 29, 927–941. [CrossRef]

46. Enroth, C.; Poulsen, L.D.; Iversen, S.; Kirpekar, F.; Albrechtsen, A.; Vinther, J. Detection of Internal N7-Methylguanosine (M7G) RNA Modifications by Mutational Profiling Sequencing. *Nucleic Acids Res.* 2019, 47, e126. [CrossRef]

47. Zhao, Y.; Kong, L.; Pei, Z.; Li, F.; Li, C.; Sun, X.; Shi, B.; Ge, J. M7G Methyltransferase METTL1 Promotes Post-Ischemic Angiogenesis via Promoting VEGFA MRNA Translation. *Front. Cell Dev. Biol.* 2021, 9, 642080. [CrossRef] [PubMed]

48. Furlan, M.; Delgado-Tejedor, A.; Mulroney, L.; Pelizzola, M.; Novoa, E.M.; Leonardi, T. Computational Methods for RNA Modification Detection from Nanopore Direct RNA Sequencing Data. *RNA Biol.* 2021, 18, 31–40. [CrossRef] [PubMed]

49. Kasprzak, J.M.; Czerwoniec, A.; Bujnicki, J.M. Molecular Evolution of Dihydrouridine Synthases. *BMC Bioinform.* 2012, 13, 153. [CrossRef] [PubMed]

50. Yu, F.; Tanaka, Y.; Yamashita, K.; Suzuki, T.; Nakamura, A.; Hirano, N.; Suzuki, T.; Yao, M.; Tanaka, I. Molecular Basis of Dihydrouridine Formation on TRNA. *Proc. Natl. Acad. Sci. USA* 2011, 108, 19593–19598. [CrossRef] [PubMed]

51. Drakecott, A.S.; Schaeining-Burgos, C.; Rojas-Duran, M.F.; Wilson, L.; Schärén, L.; Neugebauer, K.M.; Nachtergaele, S.; Gilbert, W.V. Transcriptome-Wide Mapping Reveals a Diverse Dihydrouridine Landscape Including MRNA. *PLoS Biol.* 2022, 20, e3001622. [CrossRef]

52. Finet, O.; Yague-Sanz, C.; Krüger, L.K.; Tran, P.; Migeot, V.; Louski, M.; Nevers, A.; Rougemaille, M.; Sun, J.; Ernst, F.G.M.; et al. Transcription-Wide Mapping of Dihydrouridine Reveals That MRNA Dihydrouridylation Is Required for Meiotic Chromosome Segregation. *Mol. Cell* 2022, 82, 404–419.e9. [CrossRef]

53. Pomerantz, S.C.; McClosey, J.A. Analysis of RNA Hydrolyzates by Liquid Chromatography-Mass Spectrometry. *Methods Enzymol.* 1990, 193, 796–824. [CrossRef]

54. Wang, Y.; Wang, J.; Li, X.; Xiong, X.; Wang, J.; Zhou, Z.; Zhu, X.; Gu, Y.; Dominissini, D.; He, L.; et al. N1-Methyladenosine Methylation in TRNA Drives Liver Tumourigenesis by Regulating Cholesterol Metabolism. *Nat. Commun.* 2021, 12, 6314. [CrossRef]

55. Cozen, A.E.; Quartley, E.; Holmes, A.D.; Hrabeta-Robinson, E.; Phizicky, E.M.; Lowe, T.M. ARM-Seq: AlkB-Facilitated RNA Methylation Sequencing Reveals a Complex Landscape of Modified TRNA Fragments. *Nat. Methods* 2015, 12, 879–884. [CrossRef] [PubMed]
84. Jackman, J.E.; Montange, R.K.; Malik, H.S.; Phizicky, E.M. Identification of the Yeast Gene Encoding the tRNA M1G Methyltransferase Responsible for Modification at Position 9. *RNA* 2003, 9, 574–585. [CrossRef]

85. Ranasinghe, R.T.; Challand, M.R.; Ganzinger, K.A.; Lewis, B.W.; Softley, C.; Schmied, W.H.; Horrocks, M.H.; Shivji, N.; Chin, J.W.; Spencer, J.; et al. Detecting RNA Base Methylation in Single Cells by In Situ Hybridization. *Nat. Commun.* 2018, 9, 655. [CrossRef]

86. Leger, A.; Amaral, P.P.; Pandolfini, L.; Capitanchik, C.; Capraro, F.; Miano, V.; Migliori, V.; Toolan-Kerr, P.; Sideri, T.; Enright, A.J.; et al. RNA Modifications Detection by Comparative Nanopore Direct RNA Sequencing. *Nat. Commun.* 2021, 12, 7198. [CrossRef]

87. Shippy, D.C.; Fadl, A.A. tRNA Modification Enzymes GidA and MnmE: Potential Role in Virulence of Bacterial Pathogens. *Int. J. Mol. Sci.* 2014, 15, 18267–18280. [CrossRef]

88. Noma, A.; Sakaguchi, Y.; Suzuki, T. Mechanistic Characterization of the Sulfur-Relay System for Eukaryotic 2-Thiouridine Biogenesis at tRNA Wobble Positions. *Nucleic Acids Res.* 2009, 37, 1335–1352. [CrossRef]

89. Vendelø, F.A.P.; Murphy, F.V.; Cantara, W.A.; Lensch, B.G.; Gustilo, E.M.; Sproat, B.; Malkiewicz, A.; Agris, P.F. Human tRNA(Lys5)(UUU) Is Pre-Structured by Natural Modifications for Cognate and Wobble Codon Binding through Keto-Enol Tautomerism. *J. Mol. Biol.* 2012, 416, 467–485. [PubMed]

90. Noma, A.; Minato, Y.; Ikeuchi, Y.; Suzuki, T. Biosynthesis of Wybutosine, a Hyper-Modified Nucleoside in Eukaryotic Phenylalanine tRNA. *EMBO J.* 2006, 25, 2142–2154. [CrossRef] [PubMed]

91. Perche-Letuvé, P.; Molle, T.; Forouhar, F.; Mulliez, E.; Atta, M. Wybutosine Biosynthesis: Structural and Mechanistic Overview. *RNA Biol.* 2014, 11, 1508–1518. [CrossRef] [PubMed]

92. Jin, G.; Xu, M.; Zou, M.; Duan, S. The Processing, Gene Regulation, Biological Functions, and Clinical Relevance of N4-Acetylcytidine on RNA: A Systematic Review. *Mol. Ther. Nucleic Acids* 2020, 20, 13–24. [CrossRef] [PubMed]

93. Sas-Chen, A.; Thomas, J.M.; Matzov, D.; Capraro, F.; Miano, V.; Nance, K.D.; Nie, R.; Bryson, K.M.; Shachar, R.; Liman, G.L.S.; Burkhardt, B.W.; et al. Dynamic RNA Acetylation Revealed by Quantitative Cross-Evolutionary Mapping. *Nature* 2020, 583, 638–643. [CrossRef] [PubMed]

94. Arango, D.; Sturgill, D.; Alhusaini, N.; Dillman, A.A.; Sweet, T.J.; Hanson, G.; Hosogane, M.; Nanan, K.K.; Mandler, M.D.; et al. Acetylation of Cytidine in MRNA Promotes Translation Efficiency. *Cell* 2018, 175, 1872–1886.e24. [CrossRef] [PubMed]

95. Tardu, M.; Jones, J.D.; Kennedy, R.T.; Lin, Q.; Koutmou, K.S. Identification and Quantification of Modified Nucleosides in Saccharomyces Cerevisiae MRNAs. *ACS Chem. Biol.* 2019, 14, 1403–1409. [CrossRef]

96. Bohrsack, K.E.; Kleiber, N.; Lemus-Diaz, N.; Bohrsack, M.T. Roles and Dynamics of 3-Methylcytidine in Cellular MRNAs. *Trends Biochem. Sci.* 2022, 47, 596–608. [CrossRef] [PubMed]

97. Marchand, V.; Ayadi, L.; Bourguignon-Igel, V.; Helm, M.; Motorin, Y. AlkAriReal-Seq: A Highly Sensitive and Specific Method for Simultaneous Mapping of 7-Methyl-Guanosine (M7G) and 3-Methyl-Cytosine (M3C) in MRNAs by High-Throughput Sequencing. *Methods Mol. Biol.* 2021, 2298, 77–95. [CrossRef]

98. Cui, J.; Liu, Q.; Sendinc, E.; Shi, Y.; Gregory, R.I. Nucleotide Resolution Profiling of M3C RNA Modification by HAC-Seq. *Nucleic Acids Res.* 2021, 49, e27. [CrossRef] [PubMed]

99. Zheng, G.; Qin, Y.; Clark, W.C.; Dai, Q.; Yi, C.; He, C.; Lambowitz, A.M.; Pan, T. Efficient and Quantitative High-Throughput tRNA Sequencing. *Nat. Methods* 2015, 12, 835–837. [CrossRef] [PubMed]

100. Behrens, A.; Roedchicka, G.; Nedialkova, D.D. High-Resolution Quantitative Profiling of tRNA Abundance and Modification Status in Eukaryotes by Mim-tRNAasq. *Mol. Cell* 2021, 81, 1802–1815.e7. [CrossRef] [PubMed]

101. Gogakos, T.; Brown, M.; Garzia, A.; Meyer, C.; Hafner, M.; Tuschl, T. Characterizing Expression and Processing of Precursor and Mature Human tRNAs by Hydro-tRNAasq and PAR-CLIP. *Cell Rep.* 2017, 20, 1463–1475. [CrossRef]

102. Yokogawa, T.; Nomura, Y.; Yasuda, A.; Ogino, H.; Hiura, K.; Nakada, S.; Oka, N.; Ando, K.; Kawamura, T.; Hirata, A.; et al. Identification of a Radical SAM Enzyme Involved in the Synthesis of Archaeosine. *Nat. Chem. Biol.* 2019, 15, 1148–1155. [CrossRef] [PubMed]

103. Turner, B.; Burkhardt, B.W.; Weidenbach, K.; Ross, R.; Limbach, P.A.; Schmitz, R.A.; de Crey-Lagard, V.; Stedman, K.M.; Santangelo, T.J.; Iwata-Reuyl, D. Archaeosine Modification of Archaeal tRNA: Role in Structural Stabilization. *J. Bacteriol.* 2020, 202, e00448-19. [CrossRef] [PubMed]

104. Lentini, J.M.; Fu, D. Monitoring the 5-Methoxycarbonylmethyl-2-Thiouridine (Mcm5s2U) Modification Utilizing the Gamma-Toxin Endonuclease. *Cell Rep.* 2020, 432, 913–929. [CrossRef] [PubMed]

105. Jäger, G.; Leipuviene, R.; Pollard, M.G.; Qian, Q.; Björk, G.R. The Conserved Cys-X1-X2-Cys Motif Present in the TtcA Protein Is Required for the Thiolation of Cytidine in Position 32 of tRNA from Salmonella Enterica Serovar Typhimurium. *J. Bacteriol.* 2020, 12, 13851–9. [CrossRef] [PubMed]

106. Spencer, J.; et al. Detecting RNA Base Methylations in Single Cells by in Situ Hybridization. *Cell Rep.* 2018, 23, 197–216. [CrossRef] [PubMed]

107. Hirata, A.; Suzuki, T.; Nagano, T.; Fujii, D.; Okamoto, M.; Sora, M.; Lowe, T.M.; Kanai, T.; Atomi, H.; Suzuki, T.; et al. Distinct Modified Nucleosides in tRNAtrp from the Hyperthermophilic Archaeon Thermococcus Kodakarensis and Requirement of tRNA M2G10/M2 G10 Methyltransferase (Archaeal Trm11) for Survival at High Temperatures. *J. Bacteriol.* 2019, 207, e00448-19. [CrossRef] [PubMed]
108. Bavi, R.S.; Sambhare, S.B.; Sonawane, K.D. MD Simulation Studies to Investigate Iso-Energetic Conformational Behaviour of Modified Nucleosides m(2)G and m(2)G Present in TRNA. *Comput. Struct. Biotechnol. J.* 2013, 5, e201302015. [CrossRef] [PubMed]

109. Lamichhane, T.N.; Arimbasseri, A.G.; Rijal, K.; Iben, J.R.; Wei, F.Y.; Tomizawa, K.; Marai, R.J. Lack of TRNA-16A Modification Causes Mitochondrial-like Metabolic Deficiency in S. Pombe by Limiting Activity of Cytosolic TRNATyr, Not Mito-TRNA. *RNA* 2016, 22, 583–596. [CrossRef] [PubMed]

110. Schweizer, U.; Bohleber, S.; Fradejas-Villar, N. The Modified Base Isopenosyladenosine and Its Derivatives in TRNA. *RNA Biol.* 2017, 14, 1197–1208. [CrossRef]

111. Pereira, M.; Francisco, S.; Varanda, A.S.; Santos, M.; Santos, M.A.S.; Soares, A.R. Impact of TRNA Modifications and TRNA-Modifying Enzymes on Proteostasis and Human Disease. *Int. J. Mol. Sci.* 2018, 19, 3738. [CrossRef] [PubMed]

112. Perrochia, L.; Crozat, E.; Hecker, A.; Zhang, W.; Bareille, J.; Collinet, B.; van Tilburg, H.; Forterre, P.; Basta, T. In Vitro Biosynthesis of a Universal T6A TRNA Modification in Archaea and Eukarya. *Nucleic Acids Res.* 2013, 41, 1953–1964. [CrossRef]

113. Berulava, T.; Ziehe, M.; Klein-Hitpass, L.; Mladenov, E.; Thomale, J.; Rüther, U.; Horsthemke, B. FTO Levels Affect RNA Modification and the Transcriptome. *Eur. J. Hum. Genet.* 2013, 21, 317–323. [CrossRef]

114. Sharma, S.; Yang, J.; Döttmann, S.; Watzinger, P.; Köetter, P.; Entian, K.-D. Identification of Novel Methyltransferases, Bmt5 and Bmt6, Responsible for the MSU Methylation of 25S RNA in Saccharomyces Cerevisiae. *Nucleic Acids Res.* 2014, 42, 3246–3260. [CrossRef] [PubMed]

115. de Crécy-Lagard, V.; Brochier-Armanet, C.; Urbonavičius, J.; Fernandez, B.; Phillips, G.; Lyons, B.; Noma, A.; Alvarez, S.; Droogmans, L.; Armengaud, J.; et al. Biosynthesis of Wyosine Derivatives in TRNA: An Ancient and Highly Diverse Pathway in Archaea. *Mol. Biol. Evol.* 2010, 27, 2062–2077. [CrossRef] [PubMed]

116. Urbonavičius, J.; Tauraitė, D. Biochemical Pathways Leading to the Formation of Wyosine Derivatives in TRNA of Archaea. *Biomolecules* 2020, 10, 1627. [CrossRef]

117. Dutta, N.; Deb, I.; Sarzynska, J.; Lahiri, A. Inosine and Its Methyl Derivatives: Occurrence, Biogenesis, and Function in RNA. *Prog. Biophys. Mol. Biol.* 2022, 169–170, 21–52. [CrossRef]

118. Tanzer, A.; Hofacker, I.L.; Lorenz, R. RNA Modifications in Structure Prediction—Status Quo and Future Challenges. *Methods* 2019, 156, 32–39. [CrossRef]

119. Wolk, S.K.; Mayfield, W.S.; Gelines, A.D.; Astling, D.; Guillot, J.; Brody, E.N.; Janjic, N.; Gold, L. Modified Nucleotides May Have Enhanced Early RNA Catalysis. *Proc. Natl. Acad. Sci. USA* 2020, 117, 8236–8242. [CrossRef]

120. Taoka, M.; Nobe, Y.; Yamaki, Y.; Matsumoto, K.; Ishikawa, K.; Yamauchi, Y.; Hirota, K.; Nakayama, H.; Takahashi, N.; et al. Landscape of the Complete RNA Chemical Modifications in the Human 80S Ribosome. *Nucleic Acids Res.* 2018, 46, 9289–9298. [CrossRef] [PubMed]

121. Legrand, C.; Tuorto, F.; Hartmann, M.; Liebers, R.; Jacob, D.; Helm, M.; Lyko, F. Statistically Robust Methylation Calling for Whole-Transcriptome Bisulfite Sequencing Reveals Distinct Methylation Patterns for Mouse RNAs. *Genome Res.* 2017, 27, 1589–1596. [CrossRef] [PubMed]

122. Hoernes, T.P.; Hüttenhofer, A.; Erlacher, M.D. MRNA Modifications: Dynamic Regulators of Gene Expression? *RNA Biol.* 2016, 13, 760–765. [CrossRef]

123. Tan, K.-T.; Ding, L.-W.; Wu, C.-S.; Tenen, D.G.; Yang, H. Repurposing RNA Sequencing for Discovery of RNA Modifications in Clinical Cohorts. *Sci. Adv.* 2021, 7, eabd2605. [CrossRef]

124. Shelton, S.B.; Reinsborough, J.S.; Xhemaı̈lce, B. Who Watches the Watchmen: Roles of RNA Modifications in the RNA Interference Pathway. *PloS Genet.* 2016, 12, e1006139. [CrossRef]

125. Lee, J.-H.; Wang, R.; Xiong, F.; Krakowiak, J.; Liao, Z.; Nguyen, P.T.; Moroz-Omori, E.V.; Shao, J.; Zhu, X.; Bolt, M.J.; et al. Enhancer RNA M6A Methylation Facilitates Transcriptional Condensate Formation and Gene Activation. *Mol. Cell* 2021, 81, 3368–3385.e9. [CrossRef] [PubMed]

126. Lamichhane, T.N.; Arimbasseri, A.G.; Rijal, K.; Iben, J.R.; Wei, F.Y.; Guo, J.; Ma, H.; Shen, B.; Qian, S.-B. M6A in MRNA Coding Regions Promotes Translation via the YTHDC2. *Nat. Commun.* 2019, 10, 5332. [CrossRef]

127. Chen, T.; Hao, Y.-J.; Zhang, Y.; Li, M.-M.; Wang, M.; Han, W.; Wu, Y.; Lv, Y.; Hao, J.; Wang, L.; et al. M(6)A RNA Methylation Is Regulated by MicroRNAs and Promotes Reprogramming to Pluripotency. *Cell Stem Cell* 2015, 16, 289–301. [CrossRef]

128. Jiang, X.; Liu, B.; Nie, Z.; Duan, L.; Xiong, Q.; Jin, Z.; Yang, C.; Chen, Y. The Role of M6A Modification in the Biological Functions and Diseases. *Signal Transduct. Target. Ther.* 2021, 6, 74. [CrossRef]

129. Ren, W.; Lu, J.; Huang, M.; Gao, L.; Li, D.; Wang, G.G.; Song, J. Structure and Regulation of ZCCHC4 in M6A-Methylation of 28S RRNA. *Nat. Commun.* 2019, 10, 5042. [CrossRef] [PubMed]

130. Alarcon, C.R.; Goodarzi, H.; Lee, H.; Liu, X.; Tavazoie, S.; Tavazoie, S.F. HNRPAPA2B1 Is a Mediator of m(6)A-Dependent Nuclear RNA Processing Events. *Cell* 2015, 162. [CrossRef] [PubMed]
134. Blazie, S.M.; Takayanagi-Kiya, S.; McCulloch, K.A.; Jin, Y. Eukaryotic Initiation Factor EIF-3.G Augments mRNA Translation Efficiency to Regulate Neuronal Activity. eLife 2021, 10, e68336. [CrossRef] [PubMed]

135. Dominissini, D.; Moshtich-Moshkovitz, S.; Schwartz, S.; Salmon-Divon, M.; Ungr, L.; Osenberg, S.; Cesarks, K.; Jacob-Hirsch, J.; Amariglio, N.; Kupiec, M.; et al. Topology of the Human and Mouse M6A RNA Methylopes Revealed by M6A-Seq. Nature 2012, 485, 201–206. [CrossRef]

136. Grozhik, A.V.; Linder, B.; Olerin-George, A.O.; Jaffrey, S.R. Mapping M6A at Individual-Nucleotide Resolution Using Crosslinking and Immunoprecipitation (MCILP). Methods Mol. Biol. 2017, 1562, 55–78. [CrossRef]

137. Chen, K.; Lu, Z.; Wang, X.; Fu, Y.; Luo, G.-Z.; Liu, N.; Han, D.; Dominissini, D.; Dai, Q.; Pan, T.; et al. High-Resolution N(6)-Methyladenosine (m(6)A) Map Using Photo-Crosslinking-Assisted m(6)A Sequencing. Angew. Chem. Int. Ed. 2015, 54, 1587–1590. [CrossRef]

138. Li, X.; Xiong, X.; Yi, C. Epitranscriptome Sequencing Technologies: Decoding RNA Modifications. Nat. Methods 2016, 14, 23–31. [CrossRef]

139. Deng, L.-J.; Deng, W.-Q.; Fan, S.-R.; Chen, M.-F.; Qi, M.; Lu, W.-Y.; Qi, Q.; Tiwari, A.K.; Chen, J.-X.; Zhang, D.-M.; et al. M6A Modification: Recent Advances, Anticancer Targeted Drug Discovery and Beyond. Mol. Cancer 2022, 21, 52. [CrossRef]

140. Gott, J.M.; Emeson, R.B. Functions and Mechanisms of RNA Editing. Annu. Rev. Genet. 2000, 34, 499–531. [CrossRef]

141. Bazak, L.; Haviv, A.; Barak, M.; Jacob-Hirsch, J.; Deng, P.; Zhang, R.; Isaacs, F.J.; Rechavi, G.; Li, J.B.; Eisenberg, E.; et al. A-to-I RNA Editing Occurs at over a Hundred Million Genomic Sites, Located in a Majority of Human Genes. Genome Res. 2014, 24, 365–376. [CrossRef] [PubMed]

142. Rafels-Ybern, A.; Torres, A.G.; Grau-Bove, X.; Ruiz-Trillo, I.; Ribas de Pouplana, L. Codon Adaptation to TRNAs with Inosine Modification at Position 34 Is Widespread among Eukaryotes and Present in Two Bacterial Phyla. RNA Biol. 2018, 15, 500–507. [CrossRef] [PubMed]

143. Zhou, W.; Karcher, D.; Bock, R. Importance of Adenosine-to-Inosine Editing Adjacent to the Anticodon in an Arabidopsis Alanine TRNA under Environmental Stress. Nucleic Acids Res. 2013, 41, 3362–3372. [CrossRef] [PubMed]

144. Edmonds, C.G.; Crain, P.F.; Gupta, R.; Hashizume, T.; Hocart, C.H.; Kowalak, J.A.; Pomerantz, S.C.; Stetter, K.O.; McCloskey, J.A. Origins and Evolution of ADAR-Mediated RNA Editing. IUBMB Life 2016, 68, 1142–1150. [CrossRef] [PubMed]

145. Nishikura, K. A-to-I Editing of Coding and Non-Coding RNAs by ADARs. Nat. Rev. Mol. Cell Biol. 2009, 10, 459–468. [CrossRef] [PubMed]

146. Levanon, E.Y.; Eisenberg, E.; Yelin, R.; Nemzer, S.; Hallegger, M.; Shemesh, R.; Fligelman, Z.Y.; Shoshan, A.; Pollock, S.R.; Sztybel, R. RNA Editing Occurs at over a Hundred Million Genomic Sites, Located in a Majority of Human Genes. J. Bacteriol. 1991, 173, 3138–3148. [CrossRef] [PubMed]

147. Liang, X.-H.; Liu, Q.; Fournier, M.J. Loss of rRNA modifications in the decoding center of the ribosome impairs translation and strongly delays pre-rRNA processing. RNA 2009, 15, 1716–1728. [CrossRef] [PubMed]

148. Liang, X.-H.; Liu, Q.; Fournier, M.J. Step aside CRISPR, RNA Editing Is Taking Off. Nature 2020, 587, 404–406. [CrossRef] [PubMed]

149. Wright, A.; Vissel, B. The Essential Role of AMPA Receptor GluR2 Subunit RNA Editing in the Normal and Diseased Brain. Front. Mol. Neurosci. 2012, 5, 34. [CrossRef]

150. Gott, J.M.; Emeson, R.B. Functions and Mechanisms of RNA Editing. Annu. Rev. Genet. 2000, 34, 499–531. [CrossRef]

151. Levitsky, L.I.; Kliuchnikova, A.A.; Karpov, D.S.; Ivanov, M.V.; Pyatnitskiy, M.A.; Kalinina, O.V.; Gorshkov, M.V.; Moshkovskii, S.A. Adenosine-to-Inosine RNA Editing in Mouse and Human Brain Proteomes. Proteomics 2019, 19, e1900195. [CrossRef] [PubMed]

152. Kliuchnikova, A.A.; Gornachov, A.O.; Levitsky, L.I.; Pyatnitskiy, M.A.; Novikova, S.E.; Kuznetsova, K.G.; Ivanov, M.V.; Ilina, I.Y.; Farafonova, T.E.; Zgoda, V.G.; et al. Posttranscriptional Modification of TRNA in Thermophilic Archaea (Archaeobacteria). Int. J. Mol. Sci. 2020, 21, 1001–1005. [CrossRef]

153. Hundley, H.A.; Bass, B.L. ADAR Editing in Double-Stranded UTRs and Other Noncoding RNA Sequences. Trends Biochem. Sci. 2010, 35, 377–383. [CrossRef]

154. Reardon, S. Step aside CRISPR, RNA Editing Is Taking Off. Nature 2020, 587, 404–406. [CrossRef] [PubMed]

155. Wright, A.; Vissel, B. The Essential Role of AMPA Receptor GluR2 Subunit RNA Editing in the Normal and Diseased Brain. Front. Mol. Neurosci. 2012, 5, 34. [CrossRef]

156. Yang, Y.; Okada, S.; Sakurai, M. Adenosine-to-Inosine RNA Editing in Neurological Development and Disease. Nucleic Acids Res. 2021, 49, 999–1013. [CrossRef]

157. Levitsky, L.I.; Kliuchnikova, A.A.; Kuznetsova, K.G.; Karpov, D.S.; Ivanov, M.V.; Pyatnitskiy, M.A.; Kalinina, O.V.; Gorshkov, M.V.; Moshkovskii, S.A. Adenosine-to-Inosine RNA Editing in Mouse and Human Brain Proteomes. Proteomics 2019, 19, e1900195. [CrossRef] [PubMed]

158. Roovers, M.; Hale, C.; Tricot, C.; Terns, M.P.; Terns, R.M.; Grosjean, H.; Droogmans, L. Formation of the conserved pseudouridine (ψ) in tRNAs under Environmental Stress. Nucleic Acids Res. 2012, 40, 3449–3456. [CrossRef] [PubMed]

159. Becker, H.F.; Motorin, Y.; Planta, R.J.; Grosjean, H. The Yeast Gene YNL292w Encodes a Pseudouridine Synthase (Pus4) Catalyzing the Formation of ψ55 in Both Mitochondrial and Cytoplasmic TRNAs. Nucleic Acids Res. 1997, 25, 4493–4499. [CrossRef]

160. Davis, D.R. Stabilization of RNA Stacking by Pseudouridine. Nucleic Acids Res. 1995, 23, 5020–5026. [CrossRef] [PubMed]

161. Liang, X.-H.; Liu, Q.; Fournier, M.J. Loss of rRNA modifications in the decoding center of the ribosome impairs translation and strongly delays pre-rRNA processing. RNA 2009, 15, 1716–1728. [CrossRef] [PubMed]
162. Guzzi, N.; Muthukumar, S.; Ciesla, M.; Todisco, G.; Ngoc, P.C.T.; Madej, M.; Munita, R.; Fazio, S.; Ekström, S.; Mortera-Blanco, T.; et al. Pseudouridine-Modified TRNA Fragments Repress Aberrant Protein Synthesis and Predict Leukaemic Progression in Myelodysplastic Syndrome. Nat. Cell Biol. 2022, 24, 299–306. [CrossRef] [PubMed]

163. Bykhovskaya, Y.; Casas, K.; Mengesha, E.; Inbal, A.; Fischel-Goldsam, N. Missense Mutation in Pseudouridine Synthase 1 (PUS1) Causes Mitochondrial Myopathy and Sideroblastic Anemia (MLASA). Am. J. Hum. Genet. 2004, 74, 1303–1308. [CrossRef] [PubMed]

164. Dubin, D.T. Methylated Nucleotide Content of Mitochondrial Ribosomal RNA from Hamster Cells. J. Mol. Biol. 1974, 84, 257–273. [CrossRef]

165. Desmolaize, F.; Fabret, C.; Brégeon, D.; Rose, S.; Grosjean, H.; Douthwaite, S. A Single Methyltransferase YefA (RlmCD) Catalyses Both MSU747 and MSU1939 Modifications in Bacillus Subtilis 23S RNA. Nucleic Acids Res. 2011, 39, 9368–9375. [CrossRef]

166. Chang, Y.-H.; Nishimura, S.; Oishi, H.; Kelly, V.P.; Kuno, A.; Takahashi, S. TRMT2A Is a Novel Cell Cycle Regulator That Suppresses Cell Proliferation. Biochem. Biophys. Res. Commun. 2019, 508, 410–415. [CrossRef]

167. Ny, T.; Björk, G.R. Cloning and Restriction Mapping of the TrmA Gene Coding for Transfer Ribonucleic Acid (5-Methyluridine)-Methyltransferase in Escherichia Coli K-12. J. Bacteriol. 1980, 142, 371–379. [CrossRef]

168. Nordlund, M.E.; Johansson, J.O.; von Pawel-Rammingen, U.; Byström, A.S. Identification of the TRM2 Gene Encoding the TRNA(M5U54)Methyltransferase of Saccharomyces Cerevisiae. RNA 2000, 6, 844–860. [CrossRef]

169. Pereira, M.; Ribeiro, D.R.; Pinheiro, M.M.; Ferreira, M.; Kellner, S.; Soares, A.R. MSU54 TRNA Hypomodification by Lack of TRMT2A Drives the Generation of TRNA-Derived Small RNAs. Int. J. Mol. Sci. 2021, 22, 2941. [CrossRef]

170. Ayadi, L.; Galvanin, A.; Pichot, F.; Marchand, V.; Motorin, Y. RNA Ribose Methylation (2′-O-Methylation): Occurrence, Biosynthesis and Biological Functions. Biochim. Biophys. Acta 2019, 1862, 253–269. [CrossRef]

171. Wilkinson, M.L.; Crary, S.M.; Jackman, J.E.; Grayhack, E.J.; Phizicky, E.M. The 2′-O-Methyltransferase Responsible for Modification of Yeast TRNA at Position 4. RNA 2007, 13, 404–413. [CrossRef] [PubMed]

172. Sprinzl, M.; Horn, C.; Brown, M.; Loudovitch, A.; Steinberg, S. Compilation of TRNA Sequences and Sequences of TRNA Genes. Nucleic Acids Res. 1998, 26, 148–153. [CrossRef] [PubMed]

173. Sharma, S.; Marchand, V.; Motorin, Y.; Lafontaine, D.L.J. Identification of Sites of 2′-O-Methylation Vulnerability in Human Ribosomal RNAs by Systematic Mapping. Sci. Rep. 2017, 7, 11490. [CrossRef] [PubMed]

174. Endres, L.; Rose, R.E.; Doyle, F.; Rahn, T.; Lee, B.; Seaman, J.; McIntyre, W.D.; Fabris, D. 2′-O-Methyltransferase YefA (RlmCD) Catalyses Both MSU747 and MSU1939 Modifications in Bacillus Subtilis 23S RNA. Nucleic Acids Res. 2011, 39, 9368–9375. [CrossRef]

175. Punekar, A.S.; Shepherd, T.R.; Liljeruhm, J.; Forster, A.C.; Selmer, M. Crystal Structure of RlmM, the 2′-O-Ribose Methyltransferase Responsible for Modification of Yeast TRNA at Position 4. RNA 2007, 13, 404–413. [CrossRef] [PubMed]

176. Marcel, V.; Ghayad, S.E.; Belin, S.; Therizols, G.; Morel, A.-P.; Solano-González, E.; Vendrell, J.A.; Hacot, S.; Mertani, H.C.; Albare, M.A.; et al. P53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and RNA Methylation in Cancer. Cancer Cell 2013, 24, 318–330. [CrossRef] [PubMed]

177. Shima, H.; Igarashi, K. N 1-Methyladenosine (M1A) RNA Modification: The Key to Ribosome Control. J. Biochem. 2020, 167, 555–559. [CrossRef] [PubMed]

178. Jin, H.; Huo, C.; Zhou, T.; Xie, S. M1A RNA Modification in Gene Expression Regulation. Genes 2022, 13, 910. [CrossRef] [PubMed]

179. Saikia, M.; Fu, Y.; Pavon-Eternod, M.; He, C.; Pan, T. Genome-Wide Analysis of N1-Methyl-Adenosine Modification in Human TRNAs. RNA 2016, 10, 1317–1327. [CrossRef] [PubMed]

180. Liu, E.; Clark, W.; Luo, G.; Wang, X.; Fu, Y.; Wei, J.; Wang, X.; Hao, Z.; Dai, Q.; Zheng, G.; et al. ALKBH1-Mediated TRNA Demethylation Regulates Translation. RNA 2016, 18, 816–828.e16. [CrossRef] [PubMed]

181. Helm, M.; Giegé, R.; Florentz, C. A Watson-Crick Base-Pair-Disrupting Methyl Group (M1A9) Is Sufficient for Cloverleaf Folding of Human Mitochondrial TRNAlys. Biochemistry 1999, 38, 13338–13346. [CrossRef] [PubMed]

182. Sharma, S.; Hartmann, J.D.; Watzinger, P.; Klepper, A.; Peifer, C.; Kötter, P.; Lafontaine, D.L.J.; Entian, K.-D. A Single N1-Methyladenosine on the Large Ribosomal Subunit RNA Impacts Locally Its Structure and the Translation of Key Metabolic Enzymes. Sci. Rep. 2018, 8, 11904. [CrossRef] [PubMed]

183. Waku, T.; Nakajima, Y.; Yokoyama, W.; Nomura, N.; Kako, K.; Kobayashi, A.; Shimizu, T.; Fukamizu, A. NML-Mediated RNA Base Methylation Links Ribosomal RNA Subunit Formation to Cell Proliferation in a P53-Dependent Manner. J. Cell Sci. 2016, 129, 2382–2393. [CrossRef] [PubMed]

184. Murakami, S.; Suzuki, T.; Yokoyama, W.; Yagi, S.; Matsumura, K.; Nakajima, Y.; Harigae, H.; Fukamizu, A.; Motohashi, H. Nucleoceleolin Deficiency Impairs Embryonic Erythropoiesis. J. Biochem. 2018, 163, 413–423. [CrossRef] [PubMed]

185. Li, X.; Xiong, X.; Wang, K.; Wang, L.; Shu, X.; Ma, S.; Yi, C. Transcriptome-Wide Mapping Reveals Reversible and Dynamic N(1)-Methyladenosine Methylation. Nat. Chem. Biol. 2016, 12, 311–316. [CrossRef] [PubMed]

186. Li, X.; Xiong, X.; Zhang, M.; Wang, K.; Chen, Y.; Zhou, J.; Mao, Y.; Lv, J.; Yi, D.; Chen, X.-W.; et al. Base-Resolution Mapping Reveals Distinct M1A Methylation in Nuclear- and Mitochondrial-Encoded Transcripts. Mol. Cell 2017, 68, 993–1005.e9. [CrossRef] [PubMed]

187. Grozhik, A.V.; Olarerin-George, A.O.; Sindelar, M.; Li, X.; Gross, S.S.; Jaffrey, S.R. Antibody Cross-Reactivity Accounts for Widespread Appearance of M1A in 5′UTRs. Nat. Commun. 2019, 10, 5126. [CrossRef] [PubMed]

188. Machnicka, M.A.; Olchowik, A.; Grosjean, H.; Bujnicki, J.M. Distribution and Frequencies of Post-Transcriptional Modifications in TRNAs. RNA Biol. 2014, 11, 1619. [CrossRef] [PubMed]
216. Li, Q.; Li, X.; Tang, H.; Jiang, B.; Dou, Y.; Gorospe, M.; Wang, W. NSUN2-Mediated M5C Methylation and METTL3/METTL14-Mediated M6A Methylation Cooperatively Enhance P21 Translation. *J. Cell. Biochem.* 2017, 118, 2587–2598. [CrossRef] [PubMed]

217. Shen, Q.; Zhang, Q.; Shi, Y.; Shi, Q.; Jiang, Y.; Gu, Y.; Li, Z.; Li, X.; Zhao, K.; Wang, C.; et al. Tet2 Promotes Pathogen Infection-Induced Myelopoiesis through MRNA Oxidation. *Nature* 2018, 554, 123–127. [CrossRef]

218. Sun, Z.; Xue, S.; Zhang, M.; Xu, H.; Hu, X.; Chen, S.; Liu, Y.; Guo, M.; Cui, H. Aberrant NSUN2-Mediated M5C Modification of H19 LncRNA Is Associated with Poor Differentiation of Hepatocellular Carcinoma. *Oncogene* 2020, 39, 6906–6919. [CrossRef]

219. Sajini, A.A.; Choudhury, N.R.; Wagner, R.E.; Bornelöv, S.; Selmi, T.; Spanos, C.; Dietmann, S.; Rappsilber, J.; Michlewski, G.; Frye, M. Loss of 5-Methylcytosine Alters the Biogenesis of Vault-Derived Small RNAs to Coordinate Epidermal Differentiation. *Nat. Commun.* 2019, 10, 2550. [CrossRef] [PubMed]

220. Ma, J.; Song, B.; Wei, Z.; Huang, D.; Zhang, Y.; Su, J.; de Magalhães, J.P.; Rigden, D.J.; Meng, J.; Chen, K. M5C-Atlas: A Comprehensive Database for Decoding and Annotating the 5-Methylcytosine (M5C) Epitranscriptome. *Nucleic Acids Res.* 2022, 50, D196–D203. [CrossRef]

221. Ramanathan, A.; Robb, G.B.; Chan, S.-H. MRNA Capping: Biological Functions and Applications. *Nucleic Acids Res.* 2016, 44, 7511–7526. [CrossRef]

222. Haag, S.; Kretschmer, J.; Bohnsack, M.T. WBSCR22/Merm1 Is Required for Late Nuclear Pre-Ribosomal RNA Processing and Mediates N7-Methylation of G1639 in Human 18S rRNA. *RNA* 2015, 21, 180–187. [CrossRef] [PubMed]

223. Vinther, J. No Evidence for N7-Methylation of Guanosine (M7G) in Human Let-7e. *Mol. Cell* 2020, 79, 199–200. [CrossRef] [PubMed]

224. Kouzarides, T.; Pandolfini, L.; Barbieri, I.; Bannister, A.J.; Andrews, B. Further Evidence Supporting N7-Methylation of Guanosine (M7G) in Human MicroRNAs. *Mol. Cell* 2020, 79, 201–202. [CrossRef] [PubMed]

225. Suzuki, T. The Expanding World of TRNA Modifications and Their Disease Relevance. *Nat. Rev. Mol. Cell Biol.* 2021, 22, 375–392. [CrossRef] [PubMed]

226. Agris, P.F.; Vendex, F.A.P.; Graham, W.D. TRNA’s Wobble Decoding of the Genome: 40 Years of Modification. *J. Mol. Biol.* 2007, 366, 1–13. [CrossRef]

227. Richner, J.M.; Himansu, S.; Dowd, K.A.; Butler, S.L.; Salazar, V.; Fox, J.M.; Julander, J.G.; Tang, W.W.; Shresta, S.; Pierson, T.C.; et al. Modified MRNA Vaccines Protect against Zika Virus Infection. *Cell* 2017, 168, 1114–1125.e10. [CrossRef]

228. Chahal, J.S.; Khan, O.F.; Cooper, C.L.; McPartlan, J.S.; Tsosie, J.K.; Tilley, L.D.; Sidik, S.M.; Lourido, S.; Langer, R.; Bavari, S.; et al. Dendrimer-RNA Nanoparticles Generate Protective Immunity against Lethal Ebola, H1N1 Influenza, and Toxoplasma Gondii Challenges with a Single Dose. *Proc. Natl. Acad. Sci. USA* 2016, 113, E4133–E4142. [CrossRef]

229. Wong, S.-S.; Webby, R.J. An MRNA Vaccine for Influenza. *Nat. Biotechnol.* 2012, 30, 1202–1204. [CrossRef]

230. Endres, L.; Fasullo, M.; Rose, R. TRNA Modification and Cancer: Potential for Therapeutic Prevention and Intervention. *Future Med. Chem.* 2019, 11, 885–900. [CrossRef]

231. Zhang, X.; Su, H.; Chen, H.; Li, Q.; Liu, X.; Zhang, L.; Wu, W.K.K.; Chan, M.T.V.; Chen, H. RNA Modifications in Gastrointestinal Cancer: Current Status and Future Perspectives. *Biomedicines* 2022, 10, 1918. [CrossRef]